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PREFACE

This dissertation summarizes the work I have done during the past five
years in Dr. Kovari’s lab. I am currently working on two independent projects.
The first project addresses structure and function studies of multi-drug
resistant HIV-1 protease. Protein crystallography, enzymatic assays, in silico
modeling, and medicinal chemistry are the major tools employed to reveal the
mechanism of HIV-1 protease drug resistance, to design, synthesize, and test
the new drug candidates.
The second project focuses on structural studies of the extracellular
domain

of

human

myelin

protein

zero,

which

is

responsible

for

Charcot-Marie-Tooth disease type 1B.
More Introductory information concerning the two projects, experimental
procedures, results, and discussion are included in this dissertation. I hope
that reading my dissertation is a pleasant scientific experience for the readers.

Thanks,
Zhigang Liu
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CHAPTER 1: INTRODUCTION
1.1 Retroviruses
1.1.1 Characteristics of retroviruses

Retroviruses are a large family of enveloped RNA viruses that share some
common taxonomic components such as structure, composition, and
replicative properties(1). The diameter of these virions ranges from 80 to 100
nm with the viral glycoproteins embedded in the lipid envelope. The average
size of the viron RNA is about 7–12 kb. The viral RNA is positive, linear,
single-stranded, nonsegmented.

The hallmarks of retrovirus include the following key points. First,
retroviruses replicate in the host through the enzyme reverse transcriptase
which converts its RNA genome to linear double-stranded DNA. Second, the
enzyme integrase incorporates the DNA into the host genome. Third, the viral
genome then replicates itself as part of the host genome. The integrated viral
DNA in the host genome is refered to as a provirus.

Based on the genome organization, the retroviruses comprise two
categories: simple and complex retrovirus. Three major coding domains are
essential for all retroviruses: gag, which encodes viral structural proteins
including the matrix, the capsid, and the nucleoprotein protein; pol, which
encodes viral enzyme consisting of the reverse transcriptase and integrase;
and env, which encodes the surface and transmembrane segments of the
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envelope protein. Besides these essential major coding domains, the
replication of retroviruses entails another smaller coding domain called pro,
which encodes the enzyme protease. Retroviruses contain only these
essential elements are referred to as simple retroviruses and complex
retroviruses carry other regulatory nonvirion proteins arising from multiply
spliced messages. Figure 1.1

1.1.2 Classification of Retroviruseses

Based on the relationship in evolution, retroviruses are classified into
seven groups as shown in Table 1.1. Except for lentiviruses and the
spumaviruses, retroviruses have oncogenic potential. As shown in Table 1.1,
the human T-cell leukemia virus–bovine leukemia virus (HTLV-BLV) and the
lentiviruses and spumaviruses are complex retroviruses and all other members
are simple retroviruses.

1.2 Lentiviruses

1.2.1 Characteristics of lentiviruses

Lentivirus is a genus in retrovirus family and consists of several groups
animal viruses. All these groups have some characteristics in common (2-3).
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Figure 1.1 Genome of retrovirus (A) A simple retroviral genome. The
genetic map of an ALV contains four major coding regions, gag, pro, pol, and env.
Different reading frames are indicated by vertical displacement of the coding region.
The pro gene is encoded in the gag reading frame. The terminal noncoding
sequences include two direct repeats (R), a U5 (5′unique), and a U3 (3′unique)
sequence. (B) A complex retroviral genome. The genetic map of HTLV contains,
besides the major coding domains, information for two regulatory proteins, Tax and
Rex, encoded in regions (boxes) joined by RNA splicing. In this case, gag, pro, and
pol are all in different reading frames.

Source: Retroviruses 1997. John M. Coffin, Stephen H. Hugues and Harold E.
Varmus. Cold Spring Harbor Laboratory Press.
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Table 1.1 Classification of Retroviruses
Genus

Example

Virion morphologya

Genome

Avian sarcoma and
leukosis viral groupb

Rous sarcoma
virus

central, spherical core “C
particles”

simple

Mammalian B-type viral
group

mouse mammary
tumor virus

eccentric, spherical core
“B particles”

simple

Murine leukemia-related
viral group

Moloney murine
leukemia virus

central, spherical core “C
particles”

simple

Human T-cell leukemia
bovine leukemia viral

human T-cell
leukemia virus

central, spherical core

complex

D-type viral group

Mason-Pfizer
monkey virus

cylindrical
core

simple

Lentiviruses

HIV

cone-shaped core

complex

Spumaviruses

human foamy
virus

central, spherical core

complex

a

“D
particles”

Distinctive features seen in transmission electron micrographs.

Source: Retroviruses 1997. John M. Coffin, Stephen H. Hugues and Harold E.
Varmus. Cold Spring Harbor Laboratory Press.
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Clinically, lentiviruses are associated with a disease with a long incubation
period, immune deficiency, arthritis and autoimmunity. In addition, they are
involved in diseases affecting the hematopoietic system and central nervous
system.

Biologically, they are host species specific, exogenous and nononcogenic.
The virus particles show a cone-shaped nucleoid under the electron
microscope. The unintegrated circular and linear viral cDNA accumulates in
the infected cell. In addition, the infection of the cells could be latent and
persistent.

Molecularly, the genome is relatively large, more than 9kb long. The gag
gene is truncated. The envelope gene is highly glycosylated and highly
polymorphic. In addition, there is a novel central open reading frame in the viral
genome that separates the pol and env regions.

1.2.2 Classification of lentiviruses

The classification of lentiviruses is shown in Table 1.2; the classification is
based on the different hosts that are infected by the viruses.
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Table 1.2 Lentiviruses

Virus

Host

Primary cell

Clinical disorder

EIA virusa

Horse

Macrophages

Autoimmune hemolytic anemia,
Encephalopathy

Visna/maedi

Sheep

Macrophages

Encephalopathy/pneumonitis

CAE virusb

Goat

Macrophages

Arthritis, encephalopathy

BIVc

Cow

Macrophages

Lymphocytosis, CNS disease

FIVd

Cat

T cell

Immune deficiency, encephalopathy

SIVe

Primate

T cell

Immune deficiency, encephalopathy

HIVf

Human

T cell

Immune deficiency, encephalopathy and

virus

enteropathy

a

Equine infectious anemia virus, bCaprine arthritis-encephalitis virus, cBovine immune

deficiency virus ,dFeline immune deficiency virus, eSimian immune deficiency virus,
f

Human immune deficiency virus

Source: Levy, J. A. HIV and pathogenesis of AIDS -3rd Edition 2008. ASM press,
American Society for Microbiology (Editors) & HIV Sequence Compendium 2008
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1.3 HIV
1.3.1 HIV epidemiology

HIV was discovered in 1981 (4), and its classification as a member of
lentivirus was proposed one year later (5-8). Investigators first attributed AIDS
to some known pathogens such at Epstein-Barr virus, cytomegalovirus and
human T-cell leukemia virus (9-10). Later Montagnier and coworkers proved
that a new human retrovirus, similar to human T-cell leukemia virus, which
they called lymphadenopathy-associated virus (LAD), was associated with
AIDS by destruction of CD4+ cells(11). In 1984, HTLV-III was identified by
Gallo et al to be the pathogen of AIDS (12-15). In addition, Levy and his
colleagues

reported

that

they

had

identified

a

retrovirus

called

AIDS-associated retrovirus (ARV) that caused AIDS(16). It was proven later
that LAD and HTLV-III were the same virus. In 1986, a new name, HIV, was
given to these viruses by the International Committee on Taxonomy of
Viruses(17).

Another strain called HIV-2 was discovered in West Africa shortly after the
discovery of HIV-1 (18). Both HIV-1 and HIV-2 lead to AIDS despite the more
than 55% difference at the level of RNA sequence. The rest of this thesis will
discuss HIV-1 only.

According to the AIDS epidemic update December 2009 by the Joint
United Nations Programm on HIV/AIDS (UNAIDS) and the World Health
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Organization (WHO), 33.3 million people were living with HIV, 2.6 million were
newly infected and 1.8 million died of HIV in 2009. The global distribution of
HIV infection is summarized in Figure 1.2 (19).

1.3.2 HIV pathogenesis

In the initial stage of an acute HIV infection, HIV most likely attaches to
host cells at the site of viral entry, such as activated lymphocytes, dendritic
cells, or macrophages in the mucosae or the lymphoid tissues (20-21). The
infection is established by the translocation of the HIV from the entry site to
local lymph nodes (21-22). Within five to seven days of infection, as many
as >107 viral RNA molecules per ml of plasma may be detected. After 10 to 14
days, up to 200 billion CD4+ cell can be infected and destroyed (23). During
acute infection, CD8+ cell count increases. In addition, some innate antiviral
cytokines are also produced. However, the cytokines are too late to prevent
the establishment of infection (24-25), although they in turn cause acute
retroviral syndrome. Due to the host immune response against HIV as well as
the loss of target cells (26), the viremia is reduced dramatically within weeks in
acute infection.
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Figure 1.2 Global estimates for HIV infection as of December 2009

The CD4+ count usually returns to values close to normal after three to six
month of infection, and then it decreases steadily at a rate of 25 to 60 cells/µl
per year due to unknown reasons (27). This asymptomatic period, when the
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HIV continues to replicate at a low rate, is called the persistent period and it
leads to the heterogeneity of the HIV population under the selection pressure
of the immune system (28).The anti-HIV activity of the immune system is
thought to be meditated by CD8+ cells (29-30).

The symptomatic period develops in many HIV infection patients within ten
years when the CD4+ cell count drops below 350 cell/µl; the viral load
increases significantly, and the antiviral CD8+ immune response decreases
(31-33). In parallel there is a destruction of lymphoid tissue (34-35). In the end
stage of AIDS, CD4+ cells are still the major source of virus except in the GI
tract (36). The overall progression of HIV infection is summarized in Figure 1.3
(37).

Figure 1.3 progression of HIV infection (37).
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1.3.3 HIV structure

Figure 1.4 shows that the HIV viral p24 Gag capsid protein forms a
cone-shaped core, which is characteristic of lentiviruses.

The viron is about

100 to 120 nm in diameter (38).

The HIV viron is a lipid bilayer enveloped virus, which is derived from the
host cell membrane. Two proteins are present on the viral memberane, the
external surface envelope protein gp160 and the transmembrane protein gp41,
derived from a 160kDa precursor glycoprotein, gp160. They form spike-like
structures and later are arranged as tripod-like structure on the viral membrane
(39). Underneath the envelope is an inner shell composed of matrix protein
(MA, p17), which is required for incorporation of the Env protein in the mature
virions (40). Inside the inner shell is a conical core made of capsid protein (CA,
p24), within which resides the viral genomic RNA and the viral structural
protein nucleocapsid (NC. P7) interacting with viral RNA (41). Inside the capid
core, there are three essential viral enzymes, the viral RNA-dependent DNA
polymerase (also called reverse transcriptase, RT, p66, p51) (Figure 1.5). In
addition, Vif and Nef proteins are closely associated with the core (42-44). Vpr
protein is also found within the virion and most likely outside of the core
(45-46). Finally, some cytoskeletal proteins are found within the virions (47)
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Figure1.4 Morphology of HIV. (A) Scanning electron micrograph of budding
particles. (B) Transmission electron micrograph of HIV replication in a T cell.

Source: Levy, J. A. HIV and pathogenesis of AIDS -3rd Edition 2008. ASM press,
American Society for Microbiology (Editors) & HIV Sequence Compendium 2008
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Figure 1.5 an HIV virion with the structural and other virion proteins
identified

Source: Levy, J. A. HIV and pathogenesis of AIDS -3rd Edition 2008. ASM press,
American Society for Microbiology (Editors) & HIV Sequence Compendium 2008

1.3.4 HIV genome

The HIV genome is about 10 kb long consisting of 46 open reading frames
and two long terminal repeats as shown in Figure 1.6. 16 viral proteins are
translated based on the open reading frames. The viral mRNA can be
unspliced, singly spliced or multiply spliced. The key entity regulating the
splicing is the rev gene, which is also the product of a multiply spliced mRNA
(48).
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A full length viral mRNA, translated to Gag and Gag-Pol polyprotein later,
is the primary transcription product of HIV. The ratio of Gag and Gag-Pol
polyprotein is about 20:1 (49). The Gag-Pol polyprotein is 160kDa and
processed by HIV protease into seven individual proteins: matrix protein (p17),
capsid protein (p24), late domain (p7), nucleocapsid protein (p9), protease
(p10), reverse transcriptase/RNase (p66/p51), and integrase (p32). The first
four proteins are Gag protein and the last three are Pol protein.

Similarly, Env precursor (gp160), a translation product of a singly spliced
message from the full-length viral mRNA, is proteolytically cleaved by the host
endoprotease, furin, into the surface glycoprotein (gp120) and the
transmembrane glycoprotein (gp41) (50).

A variety of viral regulatory and accessory proteins affecting the replication
are products of the spliced mRNA, including Tat (p14), Tev (p20), Rev (p19),
Nef (p27), Vif (p23), Vpr (p15), and Vpu (p16). Tat is a transactivating protein
up-regulating HIV replication (51). Rev transports the full-length unspliced
mRNA from the nucleus to cytoplasm (48,52). The Nef protein functions in
signal transduction and cell activation (53-54). Vif, Vpr, and Vpu/Vpx proteins
are important in virion assembly, cell cycling, budding, and infectivity (51,54).
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Figure 1.6

The HIV genome and the processing of viral proteins.

1.3.5 HIV replication

The overall replication of HIV is summarized in Figure 1.7

The HIV replication cycle starts with the binding of the HIV envelope
protein gp120 to the CD4 molecule on the host T cells (55-57). Further studies
revealed that the D1 region of the CD4 molecule participates in the virus
binding directly (58-60). After the primary binding event, gp120 is displaced, to
make gp41, which is necessary for virus and cell fusion, accessible to the host
cell. The displacement of gp120 may be due to the dissociation of gp120 and
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gp41, or cleavage of gp120 (61-63). The HIV virion then enters the host cell as
a ribonucleocapsid after the virus fuses with the host cell membrane.

In the presence of viral capsid protein and the host cyclophilin A, which is a
peptidylprolyl isomerase binding to capsid protein, the HIV RNA exits from the
viral capsid (64-66).

Reverse transcription of the viral RNA to double-strained cDNA is then
carried out by the enzyme’s RNA and DNA dependent DNA polymerase, and
RNase H, with assistance from matrix protein and the nucleocapsid protein as
a chaperon protein (67-68).

The viral cDNA, together with viral matrix protein, Vpr protein, and
integrase as a preintegration complex, is transported to the nucleus as a
nuclear pore complex due to a short nuclear localization signal sequence in
integrase (69-71). Matrix protein and Vpr are not essential for the
preintegration complex (72-73), although the latter may help nuclear
importation (71,73).

Inside the nucleaus, linear viral cDNA is integrated into the host cell
genome via the catalytic function of integrase and other host cell factors
(65,74). The transcriptionally active regions of the genome are the regions
where the integration primarily takes please (75-76). Among the host cell
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factors, emerin, an integral inner nuclear envelope protein, is necessary for the
HIV cDNA integration (77).

The viral mRNA transcription is initiated with some doubly spliced
transcripts of the major regulatory genes, such as tat, rev, and nef (51).

Viral assembly takes place in the host cell membrane. The viral RNA is
incorporated into the capsid core. The capsid core, in turn, buds from the host
cell membrane, where it obtains the lipid bilayer membrane. The gp120 and
gp41 are incorporated on the viral membrane via the interaction between the
cytoplasmic tail of gp41 and the Gag protein (78-79).

Two major models are proposed for the budding process(41). The lipid raft
model, states that Gag and Gag-Pol precursors localize to the lipid rafts on the
plasma membrane where sphingolipids and cholesterol are enriched (80-82).
The second model, the Trojan exosome hypothesis, states that the assembly
of HIV virions happens in multivesicular bodies which later fuse with the
plasma membrane and releases the virus as an exosome (83).
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Figure 1.7 HIV replication cycle Adapted from http://aidsinfo.nih.gov/

1.Binding and fusion 2. Reverse transcription 3. Integration

4. Transcription 5. Assembly 6. Budding
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1.4 Antiretroviral therapy
1.4.1 Principles of antiretroviral therapy

Treatments for HIV infection have evolved at an extraordinary high rate
compared to other infectious diseases. More than 20 different drugs belonging
to several categories have been discovered and developed during the past 30
years as shown in Table 1.3. These drugs inhibit essential steps in HIV viral
replication, such as virus cell entry (84-85), reverse transcription (86), viral
cDNA intergration (87), viral polyprotein cleavage (88-89), and viral maturation
(90-93). However, the emerging drug resistance, due to the lack of
proofreading ability of the HIV-1 reverse transcriptase (94-96), requires the
development of new and potent drugs to overcome the resistance problem
(97-101).

Although these drug cannot eradicate HIV completely(102), careful use of
of them can reach the following goals: reducing the HIV related morbidity,
prolonging survival, improving the quality of life, restoring and preserving
immunologic function, and preventing HIV transmission (103). However, a
single drug is not potent enough to achieve all these goals due to the rapidly
emerging drug resistance under the drug selection pressure (18,99-101).

As a result, a combined antiretroviral therapy, highly actively antiretroviral
therapy (HAART) (104-107), is currently the mainstream treatment of HIV
infection, which combines at least three drugs. The underlying rationale is: first,
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it is unlikely for the HIV virus to be resistant to three drugs in treatment naïve
patients; second, the mutation rate, including the drug resistant mutations, is
highly dependent on the viral replication rate (108). HAART, with at least three
drugs, can suppress the viral RNA below 50 copies/ml for several years (109)
and thus reduce the transmission rate (110).

However, if viral replication is not suppressed fully by the initial HAART,
the drug combination must be changed to achieve maximal suppression of
replication. However, if the full suppression of viral replication is not feasible,
even after trials of all the different drug combinations, it is acceptable to have
intervals of persisting viremia (111).

Table 1.3 Antiretroviral drugs used in the treatment of HIV infection
Adapted from FDA website.

Brand
Name

Generic Name

Manufacturer Name

Approval
Date

Atripla

efavirenz,
Squibb 12-July-06
Bristol-Myers
emtricitabine
and and Gilead Sciences
tenofovir disoproxil
fumarate

Time
to
Approval
2.5 months

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Brand
Name

Generic Name

Manufacturer Name

Approval
Date

Time
to
Approval

Combivir

lamivudine
zidovudine

27-Sep-97

3.9 months

Emtriva

emtricitabine, FTC

Gilead Sciences

02-Jul-03

10 months

Epivir

lamivudine, 3TC

GlaxoSmithKline

17-Nov-95

4.4 months

Epzicom

abacavir
lamivudine

and GlaxoSmithKline

02-Aug-04

10 months

and GlaxoSmithKline
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Hivid

zalcitabine,
Hoffmann-La Roche
dideoxycytidine,
ddC (no longer
marketed)

19-Jun-92

7.6 months

Retrovir

zidovudine,
azidothymidine,
AZT, ZDV

GlaxoSmithKline

19-Mar-87

3.5 months

Trizivir

abacavir,
zidovudine,
lamivudine

GlaxoSmithKline

14-Nov-00

10.9
months

and

Truvada

tenofovir disoproxil Gilead Sciences, Inc.
fumarate
and
emtricitabine

02-Aug-04

5 months

Videx EC

enteric
coated Bristol Myers-Squibb
didanosine, ddI EC

31-Oct-00

9 months

Videx

didanosine,
dideoxyinosine, ddI

9-Oct-91

6 months

Viread

tenofovir disoproxil Gilead
fumarate, TDF

26-Oct-01

5.9 months

Zerit

stavudine, d4T

24-Jun-94

5.9 months

Ziagen

abacavir
ABC

17-Dec-98

5.8 months

Bristol Myers-Squibb

Bristol Myers-Squibb

sulfate, GlaxoSmithKline

Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Brand
Name

Generic Name

Manufacturer Name

Approval
Date

to
Time
Approval

Intelence

etravirine

Tibotec Therapeutics

18-Jan-08

6 months

Rescriptor

delavirdine, DLV

Pfizer

4-Apr-97

8.7 months

Sustiva

efavirenz, EFV

Bristol Myers-Squibb

17-Sep-98

3.2 months

Viramune

nevirapine, NVP

Boehringer Ingelheim

21-Jun-96

3.9 months

Manufacturer Name

Approval
Date

Time
to
Approval

Agenerase amprenavir, APV

GlaxoSmithKline

15-Apr-99

6 months

Aptivus

tipranavir, TPV

Boehringer Ingelheim

22-Jun-05

6 months

Crixivan

indinavir, IDV,

Merck

13-Mar-96

1.4 months

Fortovase

saquinavir
(no Hoffmann-La Roche
longer marketed)

7-Nov-97

5.9 months

Protease Inhibitors (PIs)
Brand
Name

Generic Name
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Invirase

saquinavir
mesylate, SQV

Kaletra

Hoffmann-La Roche

6-Dec-95

3.2 months

lopinavir
and Abbott Laboratories
ritonavir, LPV/RTV

15-Sep-00

3.5 months

Lexiva

Fosamprenavir
Calcium, FOS-APV

GlaxoSmithKline

20-Oct-03

10 months

Norvir

ritonavir, RTV

Abbott Laboratories

1-Mar-96

2.3 months

Prezista

darunavir

Tibotec, Inc.

23-Jun-06

6 months

Reyataz

atazanavir
ATV

20-Jun-03

6 months

Viracept

nelfinavir mesylate, Agouron
NFV
Pharmaceuticals

14-Mar-97

2.6 months

Approval
Date

Time
to
Approval

sulfate,

Bristol-Myers Squibb

Fusion Inhibitors
Brand
Name

Generic Name

Manufacturer Name

Fuzeon

enfuvirtide, T-20

Hoffmann-La Roche & 13-Mar-03
Trimeris

6 months

Entry Inhibitors - CCR5 co-receptor antagonist
Time
to
Approval

Brand
Name

Generic Name

Manufacturer Name

Approval
Date

Selzentry

maraviroc

Pfizer

06-August-07 8 months

HIV integrase strand transfer inhibitors
Time
to
Approval

Brand
Name

Generic Name

Manufacturer Name

Approval
Date

Isentress

raltegravir

Merck & Co., Inc.

12--Oct-07 6 months

1.4.2 Mechanisms of action of antiretroviral drugs

Reverse transcriptase inhibitors: Nucleoside and nucleotide reverse
transcriptase inhibitors (NRTIs) were the first drugs developed to inhibit HIV
replication through the termination of viral DNA production and competition of
nucleosides

used

by

the

viral

polymerase.

Among

these,

3’-azido-3’-deoxythymidine (AZT) was the first drug in this category and
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reported to be effective in preventing the onset of HIV infection symptoms
(112). It was initially synthesized as a potential drug against cancer (113).
Subsequently, seven other nucleoside reverse transcriptase inhibitors have
been used in various combinations. Nucleoside inhibitors must be
phosphorylated in vivo to be active, Consequently, several nucleotide
inhibitors of reverse transcriptase have also been developed because they are
less dependent on cellular kinase activity for activation.

Four nonnucleoside reverse transcriptase inhibitors (NNRTIs) are on the
market: etravirine, delavirdine, efavirenz, and nevirapine. They function by
blocking the hydrophobic pocket within the polymerase domain of the p66
reverse transcriptase subunit. Combined with NRTIs, these NNRTIs are potent
inhibitors of HIV replication (114).

Protease inhibitors: The FDA has approved nine HIV protease
inhibitors (PIs). HIV protease is an aspartic protease that cleaves newly
synthesized HIV-1 polyproteins at nine major cleavage sites to generate the
mature protein components of an infectious HIV-1 virion. The HIV-1 gag gene
codes for three structural proteins: matrix protein (MA), capsid protein (CA),
and nucleocapsid protein (NC), while the gag-pol gene encodes both the
structural proteins (MA, CA, and NC) and three enzymes: protease (PR),
reverse transcriptase (RT), and integrase (IN). Without effective HIV-1 PR,
HIV-1 virions remain uninfectious, hence making HIV-1 protease inhibitors the
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most potent anti-AIDS drugs and essential therapeutic components of HAART
(100,105). PIs are the most potent drugs currently against HIV replication and
are used as one component of HAART. However, the bioavailability of certain
PIs and the solubility are major concerns. For example, none of the PIs
achieve a high concentration in the cerebrospinal fluid.
Integrase inhibitors: Raltegravir is an integrase inhibitor that disrupts
the incorporation of viral cDNA into the host genome. It is proposed that
raltegravir interacts with magnesium, a critical metal cofactor of integrase, in
the integrase active site to block the catalytic function of integrase (115-117).
HIV integrase is a 32 kDa protein of 288 amino acid residues. There are three
functional domains: the N-terminal domain, the catalytic core domain and the
C-terminal domain (118).
Fusion inhibitors: Enfuvirtide, which was approved by FDA in 2003, is
a linear, 36 amino acid synthetic peptide with a sequence identical to part of
the HR2 region of gp41 that competes for binding to HR1(119-120). The
antiviral activity has been demonstrated in clinical trials, despite its variability in
sensitivity against different viral strains (121-125).

Enfuvirtide blocks the

gp41-mediated membrane fusion of the virus to the host cell. In addition, there
are other drug candidates that block the gp120-CD interaction and
gp120-coreceptor interactions (126).
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1.5 Charcot-Marie-Tooth disease

This section is an introduction to the second project of my thesis,
Charcot-Marie-Tooth disease.

Charcot-Marie-Tooth disease (CMT), a hereditary motor and sensory
neuropathy (HMSN), is the most common genetic neuropathy with an incidence
of 1 in 2500 (127). The disease is named for the three physicians who first
identified it in 1886 - Jean-Martin Charcot and Pierre Marie in Paris, France,
and Howard Henry Tooth in Cambridge, England. CMT is a heterogeneous
group of disorders that affect peripheral nerves. The nervous system has two
parts: the central nervous system (CNS) including the brain and the spinal cord;
and the peripheral nervous system (PNS), which innervates the muscles and
sensory organs. Disorders that affect the peripheral nerves are called
peripheral neuropathies. Both motor and sensory functions are compromised
in CMT.

Atrophy of the foot and lower leg muscles results in foot drop and a

high-stepped gait with frequent tripping or falls. Foot deformities are also
commonly seen clinically due to weakness of the small muscles in the feet. In
the advanced stage of CMT, muscles in the patient’s hands also atrophy.
Although the onset of symptoms is often in adolescence or early adulthood,
the delayed mid-adulthood onset is not rare. Pain may occur, ranging from
mild to severe. The mobility of the patients may be also limited due to the
muscle atrophy and weakness. Usually CMT does not affect the life
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expectancy and thus is a non-fatal disease, although respiration failure may
happen rarely if the respiratory muscles are severely affected.

The PNS contains two essential components: neurons and Schwann cells.
These two components form extensive cell-cell interactions, which are
necessary for the proper functioning of the PNS. Neuronal cells dominate the
cell-cell interactions by regulating the survival, proliferation and differentiation
of Schwann cells, which are important for the process of myelination (128-129).
In turn, Schwann cells function structurally to determine the distribution of ion
channels, the maintenance of axons, and neuron development and
regeneration (130-132). If the network of the two components is disrupted, it is
thought to lead to the development of CMT. The gene mutation may occur on
either neurons or Schwann cells, or both of them, which directly or indirectly
disrupt the cell-cell interactions (133). In addition, defects in axonal transport
are commonly seen in CMT, because neurons in PNS are more sensitive to
these defects considering the length of the axons (134). Table 1.4 and Figure
1.8 demonstrate the gene mutations and protein defects on the Schwann cell
that lead to CMT (135).
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Figure 1.8. Schematic overview of a myelinating Schwann cell
highlighting the

subcellular

localization of proteins

mutated in

demyelinationg peripheral neuropathies and their binding partners (135)
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Table 1.4 Classification of demyelinating neuropathies and their
inheritance (135)

There are many forms of CMT disease, including CMT1, CMT2, CMT3,
CMT4, and CMTX. The most common subtypes will be discussed here. CMT1
with associated peripheral nervous system (PNS) demyelination is the most
frequent diagnosis. It demonstrates slowed nerve conduction velocities and
segmental demyelination upon nerve biopsy(136).

It was first found the CMT1A was linked to chromosome 17p11.2
(137-138). Later in 1991, a large segmental duplication about 1.4 Mb of DNA
was reported in two independent cases (139-140), within which the complete
peripheral myelin protein22 gene (PMP22) was mapped (141). Consequently,
defects in PMP 22 are confirmed to cause CMT1A. The duplication of
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chromosome 17p11.2 is the most common genetic mechanism of CMT1 as it
is seen in about 70% of all cases of CMT1 (142-143). Later it was reported that
deleting the same section of chromosome 17p11.2 causes hereditary
neuropathy with liability to pressure palsies (HNPP), an autosomal-dominant
condition characterized by episodic recurrent pressure palsies, events of
paralysis or paresis, at points of nerve entrapment (144). Furthermore, point
mutations, including missense, nonsense, splice site, and frameshift mutations,
in chromosome 17p11.2 were also found to cause CMT1A (141,145-147).
PMP22 is a hydrophobic 22-kDa glycoprotein of 160 amino acids with four
transmembrane domains mainly expressed by myelinating Schwann cells in
the PNS. It is only present in the compact myelin and constitutes about two to
five percent of the total PNS myelin protein (148-149). The function of PMP22
is not clear yet, but it is proposed that PMP22 may function in the initiation of
myelin spirals, regulation of growth differentiation of Schwann cells and control
of thickness and stability of myelin sheaths (150).

Myelin protein zero (MPZ) is the causative gene for the CMT1B disease,
which is much less common than CMT1A, accounting for less than five percent
of all CMT1 (142,151-152). The MPZ gene is located on chromosome 1,
region q22-q23 (151,153-154). To date, over 125 different mutations in the
MPZ gene leading to peripheral neuropathy in patients have been reported
worldwide

(http://www.molgen.ua.ac.be/CMTMutations/default.cfm).

The

distribution of the mutations is illustrated in Figure 1.9 (155). It is found that all
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mutations resulting in change or deletion of amino acid residues in MPZ give
rise to neuropathy with the only exception R215L, which instead causes a
benign polymorphism (156). Furthermore, more detailed analysis classifies the
MPZ mutations into two major groups (155). In the first group, the mutations
disrupt the intracellular processing of MPZ and are mainly associated with
early onset neuropathy(157). It is proposed that the mutated MPZ is trapped
inside the cell rather than being transported to the plasma membrane.
However, other evidence suggests that the mutated MPZ protein is expressed
on the plasma membrane, but disrupts the structure of myelin by a
dominant-negative mechanism (155,158-159). In the second group, the MPZ
mutations are associated with a late onset neuropathy since the mutations
cause only mild demyelination. The underlying mechanism is elusive but the
current hypothesis is that the mutations cause minor abnormalities in the
myelin sheath that over time may lead to aberrant Schwann cell-axon
interactions and subsequently to axonal degeneration(157). Myelin protein
zero (MPZ), associated with CMT1B, is a transmembrane protein of 219 amino
acid residues. Human MPZ consists of three domains: 125 residues constitute
the glycosylated immunoglobulin-like extracellular domain, 27 residues span
the membrane, and 67 residues represent the highly basic intracellular domain
(160-161). MPZ, a homophilic adhesion molecule(162-164), is a member of
the immunoglobulin super-family (165) and is essential for normal myelin
structure and function. It is proposed that MPZ forms homotetramers, a

31

doughnut-like structure with a hole, and interacts with the opposite
homotetramer with a head-to-head interaction (166). In vivo the MPZ knockout
mice displayed abnormal myelin that severely affects the myelination
pathway(167), and overexpression of MPZ causes congenital hypomyelination
of peripheral nerves(168). The cytoplasmic domain of MPZ is also necessary
for the proper adhesion function (169).

CMT1C is linked to chromosome 16p13.1 (170) and mutations in the
lipopolysaccharide-induced TNF factor gene (LITAF gene) (171-173). Six
mutations have been found to cause CMT1C. It is suggested that the LITAF
sequence may be involved in the ubiquitin-mediated proteosome pathway and
interactions with other proteins via the PPXY and the PSAP motifs (173).

CMT1D contains mutations in the early growth response 2 (EGR2) gene
on chromosome 10q21-22 (174). ERG2, a zinc finger transcription factor, is
critical in PNS development (175). Consequently, even before the onset of
PNS myelination, the EGR2 gene is expressed in mice and rats (176). The
regulatory functions of EGR2 include the expression of PMP22, MPZ, gap
junction protein β1 and Periaxin, and the synthesis of lipids (177-179).

CMT2E is linked to mutations in the neurofilament protein, light
polypeptide gene (NEFL), that cause reduced nerve conduction velocities,
axonal degeneration, and the presence of small onion bulbs. NEFL is located
within the cytoskeleton of myelinated axons. Neurofilaments (NF), structurally
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Figure 1.9 Mutations on the open reading frame of MPZ (155).
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and functionally important for axons, are composed of three neuron specific
proteins: NEFL 68kD, NF medium 125 kD and NF heavy 200 kD on SDS
polyacrylamide gels (180-181).
In addition, CMTX, an X-linked form of CMT, arises from a mutation in
the connexin-32 gene(182).
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CHAPTER 2: MATERIAL AND METHODS
2.1 Plasmid purification and characterization

The plasmids were transformed into DH5α E. coli and plated on LB plates
in the presence of the antibiotic, ampicilin, as a selective agent. Then a single
colony was selected and inoculated into liquid LB medium with the selective
agent. The culture was keep at 37 ºC with shaking. The plasmids were purified
with a MiniPrep purification kit (Invitrogen). The DNA concentration of the
purified plasmids was determined as a function of absorbance at 260nm. The
DNA purity was determined by the ratio of A260nm/A280nm. The plasmids were
cut by restriction enzymes and the DNA was sequenced. Aliquots of the
plasmids were prepared and stored at -80 degrees to avoid freeze and thaw
cycles and to prevent potential degradation.

2.2 Agrarose gel electrophoresis

The agrarose gel electrophoresis was carried out with the HOEFER mini
DNA electrophoresis apparatus and 0.8 to 1.0 grams of agarose that was
dissolved in 100 ml TAE buffer and heated in a microwave for one to two
minutes. After the melted agraose had cooled to 50 degrees, ethidium bromide
was added for DNA staining. The melted agraose solution was poured into the
electrophoresis apparatus. The sample loading wells were made by using a
comb with tooth dimensions of 1.5 mm thickness and 5 mm width.
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DNA samples were mixed with BlueJuice loading buffer (65% sucrose, 10
mM Tris-HCl, pH 7.58, 10 mM EDTA, 0.3% Bromophenol blue).

The gel was run at 10V/cm for one to two hours until the dye reached
about one centimeter from the bottom of the gel. The electrophoresis pattern
was viewed on a short wave ultraviolet transilluminator to visualize the DNA
stained with ethidium bromide.

2.3 E. coli. transformation

The plasmid (50ng) and competent cells (50 µl) were mixed and incubated
on ice for ten minutes to achieve maximal contact between the plasmids and
competent cells. The E.coli–DNA mixture was heat shocked at 42ºC for 20
seconds. The E.coli–DNA mixture was kept on ice for two minutes to reduce
potential damage to the competent cells. LB liquid medium (950 µl) without the
antibiotic was added to each tube and incubated at 37 ºC for one hour. Then
the liquid culture was spread on two LB plates containing the antibiotic using
200 µl and 800 µl culture respectively. The Petri dishes were grown overnight
at 37 ºC to obtain isolated single colonies.

2.4 Protein expression, purification, and dialysis

The conditions for protease expression, purification and dialysis were
highly similar between the inactive and active MDR769 HIV-1 protease. The
only difference is the pH value of the buffer at the ionic exchange
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chromatography step. The buffer pH of the inactive protease preparation is 8.6,
and the pH of the active protease preparation is 7.8. Sections 2.4.1 and 2.4.2
describe the preparation of the inactive and active HIV-1 MDR protease.

2.4.1 Inactive MDR769 HIV-1 protease

The inactive MDR769 HIV-1 protease A82T was over expressed by using
a T7 promoter expression vector in conjunction with the E. coli host, BL21
(DE3). In brief, a fresh transformant of BL21 (DE3) with the MDR769 plasmid
was cultured in 5 ml LB medium containing 100 mg/ml ampicillin for 7 hours,
which was used to inoculate 50 ml LB medium containing 100 mg/ml ampicillin
overnight. Later, the culture was inoculated into two liters of LB medium with
100 mg/ml ampicillin to an to an absorbance at 600nm of 0.1. After 4 to 6 hour
of incubation with shaking at 37ºC, the A600 was increased to 0.5 and these
cells were harvested at 10,000xg for 10 min at 4ºC by using a Sorvall RC5B
Plus centrifuge (183). The inactive MDR769 HIV-1 protease was isolated from
inclusion bodies by using a series of buffered washes, followed by denaturing
in 6 M urea. For purification of the unfolded protease, an anion exchange resin
with pH 8.6 (Q Sepharose, Amersham Biosciences) was used that allowed the
protease to pass through and the contaminants to bind. The protease was
determined to be purified greater than 95% through Coomassie blue-stained
SDS-PAGE (184).The 6M urea was removed to refold the protease by using a
series of dialysis exchanges that were carried out at 4ºC. The first buffer
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consisted of 0.2M sodium phosphate monobasic, 0.2M sodium phosphate
dibasic, 1.0M urea, 0.2% βME, and 10% glycerol. The next three buffer
changes consisted of 0.2M sodium phosphate monobasic, 0.2M sodium
phosphate dibasic, 0.2% βME, and 10% glycerol. The last two buffer changes
were 10 mM sodium acetate, 1 mM DTT and 10% glycerol (pH 5). The
protease was concentrated by Amicon to between 2 and 3 mg/ml for storage at
-80ºC in aliquots. Figure 2.1 shows the SDS gel of MDR769 HIV-1 protease.

Figure 2.1. SDS PAGE gel of MDR769 HIV-1 protease after ion exchance
column at pH 8.6. The left column was the size market. The bands on the right
were the denatured inactive MDR769 HIV-1 protease around marker level of 10K Da.
The fractions with pure protein were collected, pooled together and subjected to
dialysis in order to remove the urea and refolded the protein.
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2.4.2 Active MDR796 HIV-1 protease

The active MDR769 HIV-1 protease was over expressed by using a T7
promoter expression vector in conjunction with the E. coli host, BL21 (DE3). In
brief, a fresh transformant of BL21 (DE3) with the active MDR769 HIV-1
protease plasmid was cultured in 5 ml LB medium containing 100 mg/ml
ampicillin for 7 hours, which, in turn, was used to inoculate 50 ml LB medium
containing 100 mg/ml ampicillin overnight. Later the culture was inoculated to
two liters of LB medium with 100 mg/ml ampicillin to an A600 of 0.1. After 4 to
6 hour of incubation with shaking at 37ºC, the A600 had increased to 0.5 and
these cells were harvested at 10,000xg for 10 min at 4ºC by using a Sorvall
RC5B Plus centrifuge (183). The active MDR769 HIV-1 protease was isolated
from inclusion bodies by using a series of buffered washes, followed by
denaturing in 6 M urea. For purification of the unfolded protease, an anion
exchange resin with pH 7.8 (Q Sepharose, Amersham Biosciences) was used
that allowed the protease to pass through and the contaminants to bind. The
protease was determined to be purified greater than 95% through Coomassie
blue-stained SDS-PAGE (184).The 6M urea was removed to refold the
protease by using a series of dialysis exchanges that were carried out at 4ºC.
The first buffer consisted of 0.2M sodium phosphate monobasic, 0.2M sodium
phosphate dibasic, 1.0M urea, 0.2% βME, and 10% glycerol. The next three
buffer changes consisted of 0.2M sodium phosphate monobasic, 0.2M sodium
phosphate dibasic, 0.2% βME, and 10% glycerol. The last two buffer changes
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were 10 mM sodium acetate, 1 mM DTT and 10% glycerol (pH 5). The
protease was concentrated by Amicon to between 2 and 3 mg/ml for storage at
-80ºC in aliquots.

2.4.3 Extracellular domain of human wild type myelin protein zero

The extracellular domain of the wild type human MPZ (hP0ex) was cloned
into pMAL™-p2X vector (New England Biolabs), at the XmnI/XbaI sites. The
insertion of hP0ex downstream from the malE gene, which encoded the
maltose binding protein (MBP), resulted in a translational fusion of the E.coli
MBP to the N-terminus of hP0ex. To facilitate protein crystallization, a flexible
triple alanine linker was inserted between the MBP and hP0ex. This
polyalanine linker allowed the MBP and hP0ex domains to fold independently.
Also, in recent reported crystal structures, the presence of MBP did not disturb
the 3D structure of the target protein in crystals (185-187). In addition, the
structures of both apo-MBP (188) and maltose-bound forms (189-190) have
been determined and could be employed as search models to solve the phase
problem.

E. coli BL21 (DE3) cells were transformed with the MBP-hP0ex fusion
plasmid, and the cells were grown in LB medium supplemented with ampicillin
(100µg/ml) at 37oC to a cell density of OD600 = 0.5. Fusion protein expression
was induced with isopropylthiogalactoside (IPTG) for two hours. Cell lysates
were prepared, and the fusion protein purified twice by amylose-sepharose
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affinity chromatography (191). The final protein was concentrated to 5.0 mg/ml
in buffer of 20 mM Tris, pH 8.0, 200 mM NaCl, and 1 mM EDTA. The gel
pattern is shown in Figure 2.2

2.5 Crystallization

2.5.1 In-house crystallization screening

The inactive MDR769 HIV-1 protease variants with concentration 1.5 to
2.5 mg/ml were subjected to centrifugation to remove insoluble impurities. The
hanging drop vapor diffusion method was used to form the bipyrimidal crystals
of the inactive MDR769 HIV-1 protease. Using a matrix screen consisting of
pH values (5.5 to 8.1) versus sodium chloride (0.7 to 1.4 M), the HIV-1
protease-substrate complex crystals were formed overnight at 22 ºC. Routinely,
0.2 mm crystals in the longest dimension were obtained after 14 days of
incubation. In each well, there were two droplets, containing 1µl of protein, 1µ
of reservoir solution and 2µl of protein, 1µ of reservoir solution respectively.
The later combination was adopted to increase protein sample concentration
to facilitate the crystallization.
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Figure 2.2. The SDS PAGE gel of MBP-hP0ex fusion protein. The red arrow
indicates the band of MBP-hP0ex fusion protein. Column A was the initial pool of
MBP-hP0ex fusion protein after the first amylose-sepharose affinity chromatography
and it was not pure enough. The second amylose-sepharose affinity chromatography
gave columns 3, and 5 to 8, which were pooled together to get pure MBP-hP0ex
fusion protein.
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2.5.2 High-throughput crystallization screen (HTS)

Protein samples were sent to the Hauptman-Woodward Institute (HWI) for
high throughput crystallization screening experiments using the batch method
(1536-well micro assay plates)(192). We optimized the initial crystallization hits
with the hanging-drop vapor diffusion method in the lab. The best crystals
(hP0ex) were grown from 40% PEG 8000, 0.1 M KSCN, 0.1 M Tris, pH 11.1.
Needle shaped crystals of MBP-hP0ex fusion protein appeared within one
week at 22 ºC. The crystals were soaked for two minutes in 30% glycerol and
flash frozen for diffraction experiments.

Figure 2.3 shows the original crystallization hit from HTS and Figure 2.4
represents the crystals after condition optimization.

2.5.3 Cryoprotection of crystal

To protect the crystal from cracking when fresh frozen, two different
cryoprotectents were used. 30% glucose (W/V) and 30% glycerol (v/v) were
used respectively for HIV-1 protease and myelin protein zero crystals. Fresh
cryoprotectent was made before flash freezing the crystals. One drop of the
cryoprotectent was placed on a clean slide into which a harvested crystal was
immensed for about 30 seconds. The crystals were harvested with CyrstalCap
HT(Hampton Research), a complete crystal mounting system for manual and
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automated cryocrystallography, and were stored with aluminum CryoCanes
(Hampton Research) in liquid nitrogen.

Figure 2.3 Hit from high-throughput crystallization screen showing
crystals of the the extra-cellular domain of wild type human myelin
protein zero. The crystals of the extra-cellular domain of wild type human myelin
protein zero in the leading crystallization condition hit from the high-throughput
crystallization screen at Hauptman-Woodward Institute (HWI) using the batch method.
The leading hit condition was 20% PEG 8000, 0.2 M KSCN, 0.1 M Tris, pH 9.
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Figure 2.4 The crystals after in-house condition optimization with the
hanging drop method based the leading HTC crystallization condition
hits. Individual needle shape crystals were harvested and frozen for data collection.
The crystallization temperature was at 22 oC and the condition was 40% PEG 8000,
0.1 M KSCN, 0.1 M Tris, pH 11.1.
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2.6 Crystal diffraction data collection

Data were collected from a single crystal at the Advanced Photon
Source (APS) (LS-CAT 21), Argonne National Laboratory (Argonne, IL). The
beamline used was 21-ID-D with MD-2 diffractometer hardware and software
from EMBL for sample mounting, centering, beamline diagnostics, and data
collection. The detector was a Mar 300 CCD. Raw data were reduced with
program HKL2000.

2.7 Diffraction data analysis

2.7.1 CrystalClear

CrystalClear is a program provided by Rigaku Americas Corporation. It
incorporats the concept that data acquisition and data processing should be
combined under one common, modern interface called d*TREK, a powerful
compute engine designed to process data from all Rigaku detectors including
those at synchrotrons. As a result, it provides a complete graphical user
interface for data collection and processing, which includes instrument control,
data collection, data collection strategy, data processing, image viewing,
manipulation tools, and, continuous instrument and processing analysis
modules. In the data collection module, there were functions such as
integration, empirical and numerical absorption corrections, scaling and
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calculation of ESDs, Laue group and space group determination and
reciprocal lattice viewer.

2.7.2 HKL2000

HKL2000 was also used to reduce the diffraction data. The HKL-2000
program package was based on the extended versions of Denzo, Xdisplayf,
and Scalepack. Similar to CrystalClear, it also employs a graphical user
Interface. HKL2000 is a new, extended and significantly improved version of
the HKL-package that includes all the features of HKL plus major new options,
such as 3-D processing, that improve the integration of data from crystals with
very high mosaicity. It also processes data collected with any spindle axis
orientation and refines the direction of the spindle axis. The absorption
correction dramatically improved the anomalous signal. ????

2.7.3 CCP4

The

Collaborative

Computational

Project

Number

4

in

Protein

Crystallography was set up in 1979 to develop a comprehensive collection of
software for crystallography.

For the HIV protease drug resistance project, molecular replacement was
performed with Molrep-autoMR in CCP4 (193) with the model previously solved
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in our lab (194). Initial refinements were performed by Refmac5 (195-196). The
models were further built according to the electron density maps in program
COOT (197) as the refinement processed. Crystallographic solvent water was
added in program ARP/wARP(198). The structures were refined to the final
resolution in Refmac5. The final stereochemical parameters were checked
using PROCHECK(199). B factor analysis was done by program Temperature
Factor Analysis in CCP4. Structure superpositions and their corresponding
RMSD values were calculated with the CCP4 program Superpose Molecules
(200). Protease superpositions were based upon the Cα

atoms of residues 1

through 99..

In the MPZ structural project, CCP4 suite(193) was used to convert .sca file
to .mtz file. Molecular replacement was performed by Molrep-autoMR to get
phase information(195) in CCP4 suite of programs with the maltose binding
protein model 1ANF and rP0ex model 1NEU(166,190). The maltose molecule
was built into the difference electron density maps in the COOT program(197).
Solvent water was added using ARP/wARP program(198). The structures were
refined to resolution 2.1 Å in Refmac5. The final stereochemical parameters
were checked using PROCHECK(199),
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2.7.4 COOT

The Crystallographic Object-Oriented Toolkit (COOT) is a convenient tool
for macromolecular model building, model completion and validation. It also
displays maps and models and allows model manipulations such as
idealization, real space refinement, manual rotation/translation, rigid-body
fitting, ligand search, solvation, mutations, rotamers, Ramachandran plots,
skeletonization, non-crystallographic symmetry and more.

2.7.5 PyMol

PyMol is a molecular visualization system created by Warren Lyford
DeLano and commercialized by DeLano Scientific LLC. It is a powerful tool for
producing high quality three=dimensional images of both small molecules and
biological macromolecules.

2.7.6 PISA Server

PISA is an acronym for protein interfaces, surfaces, and assemblies. It is
an interactive tool that analyzes macromolecular interfaces, predicts probable
quaternary structures, and searches the PDB and other databases for
structurally similar interfaces. Pisa Server was used to calculate the dimer
interface of MDR769 HIV-1 protease variants (201).

49

2.8 Protease enzyme assays

The active MDR769 HIV-1 protease produced in our lab and the WT HIV-1
protease (NL4-3), purchased from AnaSpec, were cryo-protected by 50%
glycerol and stored at -20 ºC. The fluorescent substrate (FRET substrate I)
which mimicked the natural substrate peptide MA/CA with excitation/emission
wavelength 340/490 nm respectively was dissolved in DMSO at a
concentration of 500 µM (202-203). The composition of the fresh enzyme
buffer was 0.1 M sodium acetate, 1.0 M sodium chloride, 1.0 mM
ethylenediaminetetraacetic acid (EDTA), 1.0 mM dithiothreitol (DTT), 10%
dimethylsulfoxide (DMSO), 1 mg/ml bovine serum albumin (BSA), and the pH
was adjusted to 4.7. The ligand was dissolved in DMSO at a concentration of
20 mM and stored at -20 ºC. It was diluted on a two-fold series (the first
concentration is two fold higher than the next one) before enzyme assay.
A 96 well flat bottom assay plate was used for the assay. A SpectraMax M5
from Molecular Devices was used to read the fluorescent signal and SoftMax
Pro was used to plot and analyze the data.
In each well of the assay plate, 97 µl of enzyme buffer was added first.
Then, 1 µl of one of the proteases was added to the buffer to make the final
concentration 20 µM. 1 µl of ligand at different concentrations was then added
to the system. The whole system was mixed gently and incubated at 37 ºC for
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ten minutes. 1 µl of fluorescent substrate was added to make the final
concentration of 5 µM. The fluorescence signal was read at one minute
intervals for twenty minutes at 37 ºC. The IC50 value were calculated with the
program SoftMax Pro.

The fluorogenic substrate used in the enzyme assay was purchased from
AnaSpec. It is a MA/CA substrate peptide analog with the sequence
DABCYL-GABA-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS; this peptide is also
referred to as HIV protease substrate I. It was widely used for the continuous
assay for HIV protease activity. Upon the cleavage of the substrate, the
EDANS molecule fluroresces at 490nm wavelength after excitation at 340 nm.
This emission is quenched by nearby DABCYL in the uncleaved substrate.
As a result, the experiment demonstrated a time-dependent increase in
fluorescence intensity that was linearly related to the extent of substrate
hydrolysis.

2.9 Chemical synthesis

The Abbott protocol was adopted to synthesize the library of lopinavir
analogs as shown in Figure 2.5 and Figure 2.6 (204). A hydroxylethylene core
consisting of the P1 and P1’ residue was synthesized first. Next, the P2 and
P2’ residues were added to the core to obtain the final desired molecule by a
regular peptide bond coupling. The amine and carboxylic groups of
L-Phenylalanine, the starting material of the hydroxylethylene core, were
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protected with benzyl groups in step1 to obtain a benzyl ester. In step 2, the
carboxyl group was deprotected to synthesize the nitrile from the ester. In step
3 the Grignard reaction was carried out where the P1 residue was attached to
the core. At this point the core was a keto-enone and needed to be further
reduced to obtain the final hydroxyethylene core. In step 4, a reduction
reaction was used to obtain the hydroxyl group between the P1 and P1’
residues. Enantiomers were produced in the reaction and then separated on a
silica column to get the desired pure isomer (done by our collaborators). In
step 5, the free amine group was protected and the remaining benzyl groups
were removed. In step 6, the P2’ residue (acid1) was coupled to the free amine
group of P1’ residue. In step 7, the Boc protection was removed and the P2
residue (acid3) was coupled to the free amine group of the P1 residue. In my
experiment, P1 site is the side chain of Phenylalanine and P1’s site is the side
chain of Homo- Phenylalanine. The supporting documents (MS analysis
results of the reaction intermediate) for each reaction are shown in the
appendix.
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Figure 2.5 The synthetic scheme of lopinavir analog. This synthetic scheme
was adapted from the Abbott protocol. The hydroxylethylene core was synthesized in
the lab with the desired modifications on the P1 and P1’ sites of lopinavir. Four
stereoisomers were produced after the step 4, which require further purification. The
core then was coupled with prepared acid 1 and acid 3 to yield the final product of a
lopinavir analog.
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Figure 2.6 Proposed library of lopinavir analogs. The green color, red color,
blue color and purple color represents the P2, P1, P1’ and P2’ of lopinavir respectively.
P2 and P2’ were kept the same as the original lopinavir. P1 and P1’ underwent
different modifications to restore the binding affinity of lopinavir to MDR HIV-1
protease. This figure listed part of the proposed library considering the tremendous
combination of different modifications. The first four lopinavir analogs show the

modifications at P1’s site, while the last four lopinavir analogs contain
modification in P1 site.
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2.10 Construction of protease – substrate models
2.10.1 Construction of wild type HIV-1 protease – substrate
(Gag-Capsid) model

For the substrate, we used the NMR (nuclear magnetic resonance
spectroscopy) based solution structure of a large protein, the MA4CA sub
domain

of

Gag

that

includes

the

C-terminus

last

four

residues

(Ser-Gln-Asn-Tyr) of Matrix and full length CA totaling 150 residues. We
superposed the Cα atoms of P2'-P1'-P1-P2 residues from MA4CA onto the
equivalent peptide substrate residues of the crystal structure, 1KJ4 (205), with
a root mean square (RMS) delta of 0.4 Å using the LSQKAB from the CCP4
(193) suite of programs. We then replaced the peptide coordinates in 1KJ4
with the substrate, MA4CA as shown in Figure 2.7 to construct the wild type
protease with substrate docked into the active site cavity.
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Figure 2.7 Modeling the Gag-Capsid substrate into the active site cavity
of HIV-1 protease. The N-terminus of the NMR structure of Capsid (shown in yellow
on the left) with MA/CA cleavage site sequence (SQNY/PIV) was superposed onto the
corresponding residues in the heptapeptide taken from the crystal structure 1KJ4
(wild type protease in complex with the MA/CA cleavage site heptapeptide). The
Capsid was then docked into the active site cavity of the wild type protease by
replacing the peptide coordinates in 1KJ4 to obtain the final model shown on the right.
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2.10.2 Construction of MDR769HIV-1 protease – substrate
(Gag-Capsid) model

Mutation N25D was introduced in the 1TW7 (206) crystal structure in both
chains of the MDR protease dimer prior to the substrate docking. Both the
catalytic aspartates were unprotonated to represent physiological pH in wild
type as well as MDR models. The substrate was then docked into the
expanded active site cavity of the MDR protease by superposing the MDR
protease onto the wild type protease-substrate model. Residues 1 to 7, 24 to
29 and 95 to 99 were chosen for superposing the MDR protease onto the
corresponding Cα atoms of the wild type protease in the model. The
coordinates for the substrate from the wild type HIV-1 protease-substrate
model were then copied into the MDR769 coordinate file. Both the initial
models showed multiple steric clashes of the substrate with the protease flaps
(Figure 2.8 ) indicating the requirement of major conformational changes in the
protease flaps before substrate docking.
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Figure 2.8 Initial models of the protease-substrate complexes. Shown in
green is the wild type HIV-1 protease taken from 1KJ4 and in red is the MDR769HIV-1
protease taken from 1TW7, both docked with the substrate (Gag-Capsid shown in
yellow) into their active site cavities. Both models show multiple steric clashes with the
protease flaps
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2.11 Molecular dynamics simulations

The apo-protease structures taken from 1TW7 and 1KJ4 (peptide
coordinates were deleted) were initially subjected to a 5 nano second MD
simulations. All MD simulations were run using the GROMACS (207) package
with the GROMOS96 force field at a temperature of 300 K and a pressure of 1
bar. The temperature and pressure were loosely coupled using Berendsen's
procedure. Crystallographic waters were deleted from all the starting
structures and the final models were solvated with the SPC (single point
charge) (208) water model. Long range electrostatics was incorporated using
the PME (particle mesh Ewald) method with a 9 Å cutoff. After 5 nano seconds
of MD, the substrate was docked into the active site cavity and both the
models

(wild

type

protease-substrate

complex

model

and

MDR

protease-substrate complex model) were then further subjected to a 5 nano
second MD simulation using the protocol described earlier.
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CHAPTER 3: CRYSTAL STRUCTURE OF FOUR MDR769 HIV -1
PROTEASE VARIANTS
3.1 Introduction
3.1.1 Wild type HIV-1 protease
HIV-1 protease is a homodimeric, aspartic protease that is critical for the
viral maturation (209) and infectivity (210). Each monomer of the protease
consists of 99 amino acids. Because disabling the protease would significantly
slow down the viral infection, HIV-1 protease has become one of the most
important drug targets to design inhibitors to combat the HIV/AIDS problem.
Error prone viral replication randomly incorporates multiple mutations resulting
in the emergence of multidrugresistant strains under the selection pressure of
various treatment regimens. HIV-1 protease is one of the viral proteins that
have been studied in detail to understand the affect of various mutations.

3.1.2 Crystal structures of WT and MDR HIV-1 protease
It is very important to study the structures of apo-protease to understand
the overall stability of the protease dimer as well as the conformational state of
various critical domains of the protease such as flaps, 80s loops (Pro79 –
Ile84) and active site cavity. As shown in Table 3.1, there is a plethora of
structures of HIV-1 protease variants (194,206,211-218), but only two crystal
structures of MDR apo-protease strains (showing altered flap conformation)
from a total of twelve structures of apo-protease are available to date. The first
medium and high resolution crystal structures of a clinical isolate MDR769
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HIV-1 protease with a wide-open conformation of the flaps was reported by our
group and the second structure of an MDR strain with such open conformation
of flaps was reported by another group.

Table 3.1 List of currently available HIV-1 protease apo-protein structures

3.1.3 Mutations in HIV-1 protease gene
Among the mutations seen in the wild type HIV-1 protease gene, 32.32%
are constituted by the natural polymorphisms (NP) (shown in Figure 3.1a).
Such NPs are observed in the strains isolated from the treatment naïve
patients. Once the patients are started on specific treatment regimens during
the HAART (Highly active anti-retroviral therapy), the drug resistant strains of
protease are selected clinically. Depending on the combination cocktail used in
the HAART, some patients might eventually get selected for the MDR strains
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of the protease. Analysis of the drug resistance mutations (DM) from the
Stanford HIV database, revealed that, based on more than 4000 clinical
isolates, the DMs constitute 60.60% of the protease gene. Frequency
distribution of such NPs and DMs analyzed from the Stanford HIV database is
shown in Figure 3.1b. With more than 50% of the gene prone to DMs,
designing inhibitors against such a drug target can be hypothetically compared
to shooting a moving target.

3.1.4 Multi-drug resistant 769 HIV-1 protease
The MDR769 HIV-1 protease is one such challenging strains of the HIV-1
protease that resists almost all the protease inhibitors available to date in the
HAART. The MDR769 HIV-1 protease consists of a set of ten mutations in the
protease gene out of which all ten are known DMs and four out of the ten are
NPs (Figure 1a). Mutations, such as V82A and I84V due to a change from
longer side chain to short side chain, cause an overall expansion of 3 Å in the
active site cavity resulting in the loss of contacts with the inhibitors. In addition
to the active site expansion, due to the conformational rigidity acquired by the
MDR HIV-1 protease from other mutations, the flaps show a wide-open
conformation with an inter-flap distance (measured between the Cα atoms of
Il50 on either flaps) of 12.25 Å (twice that of the wild type protease). In
combination, the expanded active site cavity and the wide-open flaps cause a
highly unstable binding of the inhibitor. Thus, the MDR strain is propagated
further even in the presence of most potent inhibitors.
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Figure 3.1 Mutations in the HIV-1 protease gene. (a) Amino acid sequence of
wild type (NL43) HIV-1 protease aligned with isolate from treatment naïve patients
showing the natural polymorphisms (green), the MDR769 clinical isolate (red) and
isolate from patients that received treatment showing drug resistance mutations
(brown). (b) Frequency distribution of various natural polymorphisms (blue plot) and
drug esistance mutations (red plot) in the HIV-1 protease gene. Mutation frequency on
y-axis is plotted against the amino acid sequence of the HIV-1 protease.

3.1.5 Variants of multi-drug resistant 769 HIV-1 protease
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The current study focuses on understanding the affects of additional point
mutations on the MDR protease structure with MDR769 background
(consisting of the ten characteristic mutations). Figure 3.2 shows the mapping
of the characteristic MDR769 mutations and the additional point mutations
further analyzed in this study. There are three reasons to choose these point
mutations. First, these mutations represent the side chain changes in either
volume or polarity. Second, these mutations show high possibility in DNA
random mutations. Third, all these mutations are seen in clinical isolates and
documented by the Stanford HIV database.
The active site cavity, flaps, 80s loop and dimerization domains (Figure
3.2) were mainly analyzed. Nine clinically relevant additional point mutations,
as summarized in Table 3.2, were selected for further analysis with an
MDR769 HIV-1 protease background. Out of the nine point mutations, four
mutants (I10V, A82F, A82S and A82T) yielded diffraction quality crystals.
Crystallographic analysis of the four structures mainly geared towards
understanding: (a) the capability of additional point mutations on causing
further changes in the three-dimensional structure of the MDR769 HIV-1
protease making the multidrug-resistance problem worse and (b) if there is a
common conserved trend among the four structures that can be targeted to
design future inhibitors against an ensemble of the MDR strains.
Before we obtained the crystals and analyzed the crystal structures of the
MDR769 HIV-1 protease variants, we proposed that MDR769 HIV-1 protease
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represents the end stage form of the HIV-1 protease. As we already know, two
independent phenomena contribute the most to the drug resistance of
MDR769 HIV-1 protease. One is the wide open flaps, and the other is the
expanded active site cavity of the MDR769 HIV-1 protease. Both of the two
structural changes make the MDR769 HIV-1 protease incapable of holding
inhibitors stably and tightly in its active site cavity. The extent of the structural
changes determines the severity of the drug resistance. Larger flap distance
and larger active site cavity give rise to more drug resistance. As a result, if
additional mutations introduced to the MDR769 HIV-1 protease fail to further
open the flaps or to further expand the active site cavity, it indicates that the
conformation of MDR769 HIV-1 protease is the most resistant form of HIV-1
protease against FDA approved HIV-1 protease inhibitors and thus the end
stage form of the HIV-1 protease. On the other hand, if the additional
mutations further open the flaps and enlarge the active site cavity of MDR769
HIV-1 proteaes, then MDR769 HIV-1 protease is an intermediate toward the
the most resistant form in the evolution progress. Only the end stage form of
HIV-1 protease is worth our further investigation considering the extraordinary
mutation rate of HIV.
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Figure 3.2 Mapping the MDR769 HIV-1 protease. (a) Crystal structure (PDB
code: 1TW7) of MDR769 HIV-1 protease showing color coded domains – dimerization
domain shown in brown, active site area shown in red, 80s loops shown in green and
the wide-open flaps shown in yellow. (b) The characteristic ten mutations of the
MDR769 clinical isolate are highlighted in spheres and red spheres are the focus of
current study. (c) Domain diagram of the MDR769 HIV-1 protease showing the amino
acid residues that constitute different domains. Color codes are same as in (a).

Table 3.2 Mutations chosen in the current study

3.2 Results

66

3.2.1 Crystallization results, electron density maps, and
structure analysis
From the ten mutants with MDR769 background, only four mutants (I10V,
A82F, A82S and A82T) yielded diffraction quality crystals (Table 3.2). Mutants
I10R and I10F did not express adequately and mutants L46I, V54M and V54L
yielded crystals that diffracted only to low resolution. Crystal structures of
MDR769 HIV-1 protease variants I10V, A82F, A82S and A82T were solved
and analyzed as shown in Table 3.3. All the four structures were solved in the
space group P41212. The asymmetric unit consists of one molecule of the
protease monomer. Protease dimers for each structure were calculated by
applying the crystallographic two-fold symmetry. The 2|Fo|-|Fc| electron
density maps around the mutation area are shown in Figure 3.3a for each
mutant. Contiguous electron density was seen for all the mutants except for
A82F, where partial electron density was seen for the side chain of Phe82. As
shown in Figure 3.3b, the Cα backbone of each mutant was superposed onto
that of the wild type HIV-1 protease around the mutation area to search for any
conformational changes. No significant conformational changes were
observed at the point of additional mutation in each of the corresponding four
crystal structures. The four crystal structures were further analyzed for
conformational changes in comparison with the native MDR769 HIV-1
protease (PDB code: 1TW7). Most of the conformational changes were seen in
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the flaps and the 80s loops among the four mutants when compared to that of
the native MDR769 protease.

3.2.2 The proline switch in the MDR769 I10V mutant HIV-1
protease
The crystal structure of the MDR769 I10V HIV-1 protease variant revealed
unusual alternate conformations of Pro81 (proline switch) with a 3 Å root mean
square difference of the Cα atom of the two conformations. In the wild type
HIV-1 protease and MDR769 HIV-1 protease, the Pro81 formed a trans
peptide bond, while both cis and trans peptide bonds were observed in
MDR769 I10V mutant due to the Pro81 switch. We are the first group to report
such a significant conformational change in the 80s loop. The alternate
conformations of Pro81 are shown in Figures 3.4a (electron density) and 3.4b
(refined model). Shown in Figure 3.4c is the protease dimer showing the
conformational change in the 80s loop due to the proline switch. As shown in
Figure 3.4d, we propose that Leu23, Glu21, Asn83 and Val84 are key players
in transmitting the conformational ripple effect of the mutation at codon 10
(with an MDR769 background) to the 80s loop resulting in the proline switch.
As shown in Figure 3.5a, the intra-monomer distortion is caused by the
additional 3 Å increase in the distance between the Cα atoms of Ile50 and
Pro81 within the same monomer.
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Table 3.3

Crystallographic table of four MDR769 HIV-1 protease variants

PDB entry
3PJ6
3OQD
3OQA
3OQ7
Crystal parameters
Resolution range (Å)
27.66 – 2.25 27.62 – 1.71 27.28 – 2.25 27.23 – 1.71
Space group
P41212
P41212
P41212
P41212
Solvent content (%)
47
47
47.91
47
Data processing
No. of unique reflections
5356 (768) 12231 (1628) 5466 (764) 11367 (1108)
b
I/σ(I)
14.2 (5.3)
26.4 (2.8)
20.3 (4.8)
17.6 (2.5)
a
Rmerge (%)
7.4 (24.7)
6.1 (45.9)
7.1 (37.1)
6.0 (36.8)
Data redundancyc
3.4 (3.4)
11.3 (4.4)
6.4 (6.5)
5.8 (3.0)
Completeness (%)
97.6 (99.5)
98.9 (93)
99.7 (99.7)
93.1 (65.2)
Refinement statistics
No. of reflections used
5099
11591
5196
10806
d
Rworking (%)
24.3
19.59
20.22
19.5
e
Rfree (%)
30.41
22.81
23.77
22.39
Mean temperature factors
Protein
15.82
19.75
26.32
19.59
Main chains
15.4
18.63
25.8
18.57
Side chains
16.28
20.98
26.89
20.71
Waters
8.59
30.61
28
34.49
0.021
0.013
0.019
0.013
R.m.s.d. bond lengths (Å)
R.m.s.d. bond angles
1.94
1.34
1.82
1.4
Ramachandran plot
Most favored (%)
87.2
96.2
96.2
94.9
Additional allowed (%)
10.3
3.8
3.8
5.1
Generously allowed (%)
2.6
0
0
0
Disallowed (%)
0
0
0
0
a

Rmerge= ΣhklΣi|I(hkl)i-{I(hkl)|/ ΣhklΣiI(hkl)i , where I(hkl)i is the intensity of an

observation and I(hkl) is the mean value for its unique reflection. Summations cover
all reflections.
b

The values in the parethesis indicate the highest resolution shell.
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c

Nobs/Nunique.

d

Rwork= Σhkl|F(hkl)o- {F(hk|/ΣhklF(hkl)o

e

R free was calculated same way as R working, but with the reflections excluded from

refinement. The R free set was chosen using default parameters in Refmac 5

Figure 3.3 electron density maps and analysis of four MDR HIV-1
protease variants (a) Shown in red are the 2|Fo|-|Fc| electron density maps of the
four MDR769 HIV-1 protease variants contoured at 1.0 sigma for mutants A82T,
A82S and I10V and 0.7 sigma for A82F. Shown in stick models are the residues 80 to
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85 for mutants A82F, A82S and A82T and residues 7 to 13 for mutant I10V. (b) The C
α atoms of residues 80 to 85 (for mutants A82F, A82S and A82T shown in white)
and 7 to 13 (for I10V mutant shown in white) were superposed onto those of the wild
type HIV-1 protease (shown in green).

Figure 3.4 The proline switch in MDR769 I10V mutant. (a) 2|Fo| - |Fc| electron
density map shown in blue for the alternate conformations of the Pro81 in the
MDR769 I10V HIV-1 protease crystal structure. The black arrow points to the gap
between the back bones of the two conformations of the Pro81. (b) Stick models of
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the Pro81 showing the alternate conformations with a 3 Å shift in the Cα atoms of
the either conformations. Shown in blue is the more stable conformation pointing
towards active site cavity and the green is relatively less stable conformation pointing
away from the active site cavity. (c) MDR769 I10V HIV-1 protease dimer with
alternate conformations of the Pro81 (shown in the inset). Mutation I10V is highlighted
in pink. (d) MDR769 I10V mutant HIV-1 protease dimer showing residues Glu21,
Leu23, Asn83 and Val84 highlighted in red color stick models that are key players in
the transmission of structural changes from codon 10 to the 80s loop.
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Figure 3.5 The intra and inter monomer distances in I10V mutant. (a) The
MDR769 I10V HIV-1 protease monomer is shown in cyan color with Ile 50 and Pro81
highlighted in red. On the left is shown the intramonomer distance (14.96 Å) between
the Cα atoms of Ile50 and Pro81 within the monomer with regular conformation of
the Pro81. Shown on the right is the same protease with proline switch where the
intramonomer distance is 17.13 Å which is greater than 2 Å contributing to the
distortion of S1/S1’ pocket. (b) Surface diagram of the I10V mutant showing the top
view looking into the active site cavity (Asn25 and Asn125 highlighted in blue). Shown
on the left are the van der Waals interactions between the Ile50 (red) of one monomer
and Pro81 (red) of the second monomer with a distance of 9.31 Å between the Cα
atoms. Shown on the right is the same structure with the proline switch where the
distance has increased to 12.33 Å. This change causes unstable binding of the
inhibitors.

3.2.3 The flipped-out conformation of Phe82 side chain in the
MDR769 A82F mutant
It was hypothesized that a mutation from short side chain to a bulky side
chain should restore the lost contacts with inhibitors but instead, our crystal
structure of MDR769 A82F variant showed a flipped-out conformation of the
Phe82 side chain as shown in Figure 3.6. The electron density for the terminal
ring portion of the Phe82 side chain was discontinuous indicating a possibility

73

of flexible side chain. No alternate conformations were found for the side chain
of Phe82 even at 0.7 sigma level contoured maps.

Figure 3.6 Crystal structure of the MDR769 A82F HIV-1 protease. (a) Front
view of the protease dimer with Phe82 shown in red color stick model. (b) Top view of
the protease dimer looking into the active site cavity. Phe82 is highlighted in red color
stick model. The Phe82 ring points out of the active site cavity. (c) Side view of the
protease dimer with Phe82 highlighted in red color stick model to show the
characteristic flipped-out conformation of the Phe82 side chain.

3.2.4 The A82S and A82T mutants
Crystal structures of MDR769 A82S and A82T HIV-1 protease variants
show that the hydroxyl group on the side chain is pointing away from the active
site cavity in A82S while it is pointing towards Leu23 in A82T. Due to the Pro81
side chain next to Thr82 in the A82T mutant, the hydroxyl group of Thr82 is
repelled away from Pro81 towards Leu23 which is at a farther distance from
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Thr82. As shown in Figure 3. 7, the introduction of polarity at position 82
results in the local change of electrostatics of S1/S1’ binding pockets.

Figure 3.7 Electrostatic potential surface diagrams of wild type (PDB
code: 3HVP) monomer protease compared to that of the MDR769 A82S,
A82T and A82F mutant protease monomers. The red, blue, green and white
colors represent the regions that are negatively charged, positively charged,
uncharged polar and hydrophobic respectively. Mutants A82S and A82T show
increased polar uncharged regions in the S1/S1’ pockets that cause unstable binding
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of inhibitors with hydrophobic P1/P1’ groups. The A82F mutant shows similar
distribution as that of the wild type in the S1/S1’ pocket due to the bulky Phe82
hydrophobic side chain.

3.2.5 Dimer interface calculation and analysis
Crystal structures of all the four mutants were solved as monomers in the
space group P41212. Crystallographic two-fold symmetry was applied to
obtain the dimers for each mutant. These dimers are perfectly symmetrical and
represent the functional biological unit. Calculation and analysis of the dimer
interface contacts and surface area suggested that all four mutants including
the native MDR769 show fewer contacts compared to that of the wild type
protease. As shown in Figure 3.8a, among the four mutants, the I10V and
A82T show more contacts at the dimer interface compared to that of the native
MDR769 while mutants A82F and A82S show fewer contacts compared to that
of the native MDR769. Although all the mutants, including the native MDR769,
showed similar molecular weight to surface area ratio compared to the wild
type protease at the dimer interface, the distribution of the surface area was
found to be different. The wild type and A82F mutant protease dimers showed
relatively more surface area at the dimer interface (Figure 3.8b). The inter-flap
distance was calculated between the Cα atoms of Ile50 of either flap for all
the mutants of WT (pdb code 1KJ4), MDR769, MDR769 I10V, MDR769 A82F,
MDR769 A82S and MDR769 A82T HIV-1 potease are 6.02 Å, 12.25 Å, 12.09
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Å, 12.21 Å, 11.17 Å, and 10.35 Å respectively . All the four mutants show a
conserved trend of wide-open flaps with varying inter-flap distances. The
overall dimer stability and wide-open flaps were comparable to that of the
native MDR769 for all the four mutants.

Figure 3.8 Protease dimer interface analysis. (a) Total number of contacts
made by the atoms at dimer interface for the wild type and MDR mutants. All the four
mutants including the native MDR769 dimer have relatively fewer contacts compared
to those of the wild type HIV-1 protease. Among the four mutants, the I10V and A82T
show relatively more contacts than those of the mutant A82S and A82F. The wild type
protease dimer is more stable than that of the MDR variants. (b) Surface area at the
dimer interface is relatively more for the wild type and MDR769 A82F HIV-1 protease
variants compared to the native MDR769 and the other two mutants.
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3.3 Discussion
3.3.1 Expanded active cavity with wide open flaps
The crystal structures of all the four mutants showed an overall conserved
trend of expanded active site cavity with wide-open flaps. In the case of the
I10V mutant, due to the alternate conformation of the Pro81, when the side
chain is pointing towards the active site cavity, the protease structure looks
normal and comparable to the native MDR769 HIV-1 protease but when the
side chain is pointing away from the active site cavity, it exerts conformational
stress on the 80s loop leading to the distortion of the S1/S1’ binding pocket
besides. This results in unstable binding of the inhibitors due to loss of
contacts. This could be one of the most important mechanisms by which
MDR769 and other MDR clinical isolates are selected during the HAART. The
MDR769 I10V mutant HIV-1 protease represents the most expanded active
site cavity reported so far in the literature. The proline switch also causes the
loss of inter-monomer van der Waals interactions between the flap and the 80s
loop as shown in Figure 3.5b. In addition to the original expansion of the active
site cavity of the native MDR769 strain, the I10V mutant with the proline switch
shows an overall expansion of the active site cavity by 6 Å (Figure 3.5b)
compared to that of the wild type HIV-1 protease. Loss of inter-monomer
contacts in combination with the intra-monomer distortions caused due to
proline switch may also weaken the protease dimer. Protease variants like
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MDR769 I10V can be very challenging to the most potent inhibitors available
to date but on the other hand, such variants are lethal to the viral maturation
unless there are compensatory mutations in the substrate for a productive
catalysis.

3.3.2 The flipped-out conformation of Phe82 side chain in the
MDR769 A82F mutant
The bulky side chain of Phe82 increases the conformational stress on the
flexible 80s loop that causes its flipped-out conformation. This unusual
conformation not only causes distortion in the S1/S1’ binding pockets but also
may create a pulling affect on the monomers apart resulting in a weaker dimer.
Such protease variant can pose threat to the most potent inhibitors as well as
can decrease the viral replication/maturation unless the substrate molecule
has compensatory mutations to accommodate the distorted active site cavity
of the protease.

3.3.3 Hydrophilic changes at the HIV-1 protease S/S1’ binding
pocket due to the mutations at codon 82
Crystallographic analysis of MDR769 A82S and A82T structures suggests
that if residue 82 is mutated from a hydrophobic residue such as Val (wild type)
or Ala (native MDR769) to a polar residue such as Ser or Thr, some of the
critical hydrophobic contacts with the inhibitor especially at the P1/P1’ region
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are disrupted. Considering the architecture of the side chain, since Thr mimics
Val (wild type protease) more than Ser, the A82T mutant has less distorted
S1/S1’ pocket compared to that of the A82S mutant. Nevertheless, both
mutants challenge the hydrophobic P1 and P1’ functional groups of the
inhibitors with A82S being relatively severe compared to A82T. Thus, the
decreased hydrophobicity in the S1/S1’ binding pocket together with the
wide-open conformation of the flaps result in unstable binding of the inhibitors
leading to drug resistance. Unfortunately protease variants such as the
MDR769 A82T can be productive in the substrate catalysis aiding successful
propagation of the MDR strains.

3.3.4 The clinical significance of the four mutants on HIV-1
protease
The clinical significance of the four mutants (I10V, A82F, A82S and A82T)
was analyzed in detail from the Stanford HIV database. The frequency of
various DMs seen in a pool of clinical isolates that consist of a representative
mutation – I10V or A82F or A82S or A82T was analyzed. The A82F mutant is
associated with at least 8 other DMs based on 177 clinical isolates from
treated patients. Similarly, A82S and A82T mutations are associated with at
least 6 and 7 other DMs respectively within their pools of clinical isolates from
treated patients. On the other hand, the I10V mutation was only associated
with two other mutations (L63P and L90M) based on 495 clinical isolates (1.5
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to 5 times the size of the isolate pools for the other three mutants). This
indicates that the mutation I10V is very potent in inducing drug resistance
probably by changing the three-dimensional structure of the protease resulting
in the Pro81 switch. Thus, our current study provides new insights into the
multidrug resistance mechanisms of MDR strains of HIV-1 protease.

3.4 Conclusions
In summary, we have crystallized, solved and analyzed the structures of
four MDR769 HIV-1 protease variants. Crystal structure of I10V mutant
showed that mutation at codon 10 causes a conformational ripple affect
leading to the alternate conformations of Pro81 (proline switch). Crystal
structures of A82F, A82S and A82T indicate that mutations at codon 82 may
not necessarily restore the lost contacts and that the decreased hydrophobicity
of S1/S1’ pockets further causes loss of contacts with inhibitors.

Based on the four crystal structures presented in this article, we conclude
that the flexibility caused in 80s loops (either directly due to mutations such as
A82F, A82S and A82T or indirectly due to mutations such as I10V) not only
cause loss of contacts with the inhibitors resulting in the multidrug-resistance
problem but also result in a weaker HIV-1 protease dimer that is functionally
not as active as the wild type enzyme. However, such protease variants can
still function when there are compensatory mutations in the substrate cleavage
site to accommodate the conformational distortions in the protease binding
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pockets and the active site cavity. This study further helps to understand the
design of future inhibitors with enhanced potency.

The MDR769 HIV-1 protaese presents the end stage of the HIV-1
protease evolution in the respect of drug resistance. All the additional
mutations fail to increase further the flap distance and to expand further the
active site cavity. Without further worsening of these two structural elements,
the MDR769 HIV-1 protease structure is an excellent study target for us to
investigate the rapidly emerging drug resistance issue of HIV infection.
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CHAPTER 4: MODELING OF MDR HIV-1 PROTEASE
GAG-CAPSID (MA/CA) COMPLEXES
4.1 Introduction
4.1.1 HIV-1 protease flap distance and drug resistance
To design the best inhibitors, it is very important to understand the structure
and dynamics (219-220) of HIV-1 protease involved in binding and cleavage of
bigger substrates (221). Previously we reported a high-resolution crystal
structure (206) of multidrug-resistant (MDR) clinical isolate 769 (222) HIV-1
protease showing an expanded active site cavity (194) and wide-open flaps.
According to the active site expansion hypothesis, mutations from longer side
chain residues to shorter side chain residues decrease contact with the
protease inhibitors (PIs), thereby, decreasing their binding affinity and potency.
As illustrated in Figure. 4.1, the wild type protease shows semi-open
(apo-enzyme) (211) and closed (ligand bound) (205) conformations of the
flaps while the MDR protease shows wide-open flaps. Numerous crystal
structures of wild type HIV-1 protease (analyzed from the Protein Data Bank
(PDB)) showed closed, open and semi-open conformations of the protease
flaps with varying inter-flap distances. The inter-flap distance of the MDR
protease is roughly 6-8 Å more than that of the wild type protease. All the
inter-flap distances were measured between the Cα of Ile50 on either flap. To
date, there is only one another group that has published crystal structures of
HIV-1 protease variants showing altered conformation of the flaps (218).
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Figure 4.1 Crystal structures of HIV-1 protease with different flap
conformations. The wild type (green) protease structures showing closed (PDB
code: 1KJ4) on the left and semi-open (3PHV) on the right conformations of the flaps.
The MDR769 HIV-1 protease (red) shows wide-open conformation of the flaps.

4.1.2 Wide open conformation of MDR769 HIV-1 protease flaps

This chapter is focused on answering the question, whether the wide-open
conformation of the flaps in MDR769 HIV-1 is due to the conformational rigidity
attained by the accumulation of mutations or if it represents one of the
thermodynamically

favorable

substrate

binding

conformations.

We

hypothesized that: (a) if the wide-open conformation of the MDR protease is
caused by mutation induced conformational rigidity, then the flaps should stay
open upon energy minimization and/or molecular dynamics (MD) simulations
(contrary to what is observed in the wild type protease(223)) due to the steric
hindrance caused by the mutations in the protease gene (or) (b) if the
wide-open conformation of the MDR protease is representative of one of the
favorable substrate binding conformations, then the substrate molecule can be
easily modeled into the active site cavity of the MDR protease without steric
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clashes with the protease flaps.

4.1.3 Energy minimization of MDR769 HIV-1 protease and WT
control

In order to understand the flap movement in the MDR protease, the crystal
structure 1TW7 (MDR769 HIV-1 apo-protease) was energy minimized in the
absence of crystal contacts. 1000 steps of energy minimization showed that
the flaps of the MDR protease moveed closer towards each other while still
maintaining an inter-flap distance of at least 10 Å. As a control, we performed
the same study using wild type (PDB code: 3PHV) apo-protease, which
showed the normal flap closure with a final inter-flap distance of 4 Å. This
clearly suggests that the stable wide-open nature of the MDR protease is not
entirely due to the crystal contacts (224) as reported by other groups (225)
because the energy minimization was done in the absence of crystallographic
symmetry atoms. So we reasoned that the wide-open nature of the MDR
protease could be due to the steric hindrance caused by individual mutations
or by all the ten mutations (accumulated in the MDR protease gene) in concert.
These mutations have changed the three dimensional structure of the MDR
protease permanently such that the MDR protease shows a conformational
threshold point for flap closure beyond which the conformational rigidity
hinders the flap closure.
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4.1.4 Construction of protease – substrate models

In order to verify if the wide-open nature of the MDR protease represents
one of the thermodynamically favorable substrate binding conformations, we
modeled the natural substrate, Gag consisting of the Capsid (CA) domain only
including the Matrix/Capsid (MA/CA) cleavage site, into the expanded active
site cavity of the MDR protease and performed MD simulations. Initially we
have constructed a similar model using wild type protease to use it as a control
in our MD studies.

4.2 Results and Discussion
4.2.1

The

characteristic

wide-open

conformation

of

the

MDR769HIV-1 protease flaps
Our modeling studies revealed that the substrate (Gag-Capsid) could not
be modeled into the expanded active site cavity of the MDR769 HIV-1
protease without steric clashes. This indicates that the wide-open flaps of
MDR769 HIV-1 protease (as is from the crystal structure PDB code:1TW7) are
not open enough to accommodate a natural substrate and needs at least
two-fold further opening of the wide-open flaps of the MDR protease. On the
other hand, the molecular dynamics simulations of the apo-protease structure
of the MDR protease as well as protease-substrate complex model showed
that the wide-open flaps of MDR769 HIV-1 protease never close beyond the
threshold point set by the conformational rigidity of the MDR protease
structure. Thus, the accumulation of mutations permanently change the

86

three-dimensional structure of the MDR769HIV-1 protease resulting in a steric
hindrance for the flap closure even in the presence of substrate modeled into
the active site cavity. This steric hindrance gives the characteristic wide-open
conformation to the MDR769HIV-1 protease flaps.

4.2.2 Molecular dynamics simulations show two-fold and three-fold
opening of the flaps in the MDR and wild type HIV-1 proteases
Successful crystallographic docking of the substrate (Gag-Capsid) was
achieved only after simulating the apo proteases until the flaps are completely
open. As shown in Figure 4.2, the wild type and MDR apo-proteases were
initially subjected to a 5 ns MD to achieve a completely open conformation of
the flaps. The wild type protease showed a three-fold opening of the flaps
compared to its starting structure (IKJ4) and the MDR protease showed a
two-fold opening of the flaps compared to its starting structure (1TW7). With
the flaps completely open (inter-flap distance ~ 20 Å) the substrate was
successfully docked into the active site cavity of both wild type as well as the
MDR proteases. These protease-substrate complex models were further
subjected to 5 ns of MD as shown in Figure 4.3. Thus, the wide-open
conformation of the MDR protease does not represent one of the
thermodynamically stable substrate binding conformations because; the flaps
had to open further to accommodate the substrate.
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Figure 4.2 Substrate docking and the MD simulation method. Shown in red
is the MDR769HIV-1 protease. On the left, the apo-protease before substrate
docking, shows an inter-flap distance of 12.25 Å (characteristic wide-open flaps). In
the middle, the same apo-protease after 5 ns of MD, shows a completely open
conformation of the flaps with an inter-flap distance of 25 Å. The substrate
(Gag-Capsid) is then docked into the active site cavity without any steric clashes and
the enzyme-substrate model is further subjected to a 5 ns MD to obtain the final
complex model shown on the right.
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Figure 4.3 Molecular dynamics simulations of the protease-substrate
complex models. On the left, are shown the substrate (yellow) docked wild type
(green) and MDR769 (red) HIV-1 protease models without any steric clashes. After 5
ns of the MD simulations, the same models are shown on the right. Conformational
changes in the substrate in the wild type protease-substrate model are pointed by the
blue pointers.
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4.4.3 Substrate (Gag-Capsid) is less stable in the expanded active
site cavity of the MDR769HIV-1 protease
The radius of gyration of the MDR protease-substrate complex model did
not decrease with time during the MD in comparison to that of the wild type
protease-substrate complex model as shown in the Figure 4.4 As evident from
the fluctuating radius of gyration of the MDR protease-substrate complex
model, the MDR protease failed to form a stable enzyme-substrate complex
which could result in unproductive catalysis. The loss of stability for the
substrate modeled into the expanded active site cavity of the MDR protease
may be due to loss of contacts and uncooperative wide-open nature of the
flaps. On the other hand, if the substrate has compensatory mutations, may be
the MDR protease could form a stable enzyme-substrate complex. This
mechanism of co-evolution (226) has to be further tested and is beyond the
scope of the current study.
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Figure 4.4 Radius of gyration of the models during the MD simulation.
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The radius of gyration (Rg - nano meters) is plotted on the y-aixs against the MD
simulation time (pico seconds) on the x-axis. During a 5 ns simulation, the wild type
protease-substrate complex shows a gradual decrease in Rg (shown in panel a)
indicating an increase in the overall compactness of the model. On the other hand, the
MDR769 HIV-1 protease-substrate complex shows a fluctuation in Rg (shown in
panel b) indicating less compactness.

4.2.4 Conformational changes in the substrate (Gag-Capsid) during
the MD simulations
Conformational changes in the substrate (Gag-Capsid) were observed
during the MD simulations in the wild type protease-substrate complex model
(Figure 4.5a) but not in the MDR protease-substrate complex Figure 4.5b). The
substrate modeled into the wild type HIV-1 protease showed a movement of
13 Å in the Ala96 loop as shown in Figure 4.6. This could be due to the
alignment or readjustment of the modeled substrate in the active site cavity of
the wild type protease towards the formation of a successful enzyme-substrate
complex. On the other hand, such conformational changes were not seen in
the MDR protease-substrate complex due to the unstable binding of the
modeled substrate in the expanded active site cavity of the MDR protease.
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Figure 4.5 Root mean square deviation of the substrate molecule. The
substrate docked into the wild type protease shows a significant RMSD at Ala225
indicating a major conformational change (shown in panel a) while no such significant
conformational changes were noticed in the case of the MDR769 HIV-1 protease
model (shown in panel b)
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Figure 4.6 Conformational changes in the substrate Gag-Capsid docked
into wild type HIV-1 protease model. Wild type HIV-1 protease (green) –
substrate Gag-Capsid (yellow) before MD simulations is superposed onto the
resultant (purple) model after 5 ns of MD. The Ala225 loop shows a movement of 13
Å.
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4.2.5 Alignment of the cleavage site between the catalytic aspartic
acid residues
The orientation of the cleavage site (MA/CA) in the substrate (Gag-Capsid)
modeled into the wild type protease active site cavity has changed during the
MD simulations. In the MDR protease-substrate model, the cleavage site of the
substrate appeared to be slipped out of the catalytic site. As shown in Figure
4.7 the substrate cleavage site in MDR protease-substrate complex failed to
align the substrate cleavage site between the catalytic aspartic acid residues.
Due to the expanded active site cavity and wide-open flaps of the MDR
protease, the substrate modeled into the active site cavity was not stable
enough to re-orient the MA/CA cleavage site towards a productive catalysis.
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Figure 4.7 Substrate cleavage site alignment in the protease active site.
Substrate cleavage site Asn-Tyr-/-Pro-Ile orientation before MD run is shown in cyan
color and the same after 5 ns of MD run is shown in yellow for wild type HIV-1
protease complex model and orange for the MDR HIV-1 protease complex model. In
the wild type model, the cleavage site is oriented favorably for efficient catalysis, on
the other hand, the cleavage site slips out of the catalytic site indicating less efficient
catalysis in the MDR model.
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4.2.6 Implication of MDR769HIV-1 protease substrate (Gag-Capsid)
modeling studies to drug resistance
Based on our analysis, we report that the conformational rigidity of the
MDR769 HIV-1 protease, in addition to the expanded active site cavity,
prohibits formation of a stable enzyme-substrate complex, which would result
in reduced catalysis. In the case of small molecule PIs, we predict a similar
behavior where, if the PI is not potent enough to induce closure of the
wide-open flaps, then that PI is not stable in the expanded active site cavity.
Due to lost contacts resulting in unsuccessful enzyme inhibition, one can
expect the emergence of multidrug-resistance. Thus, the MDR769 HIV-1
protease, due to its conformational rigidity, poses a great challenge to the
current PIs that are used in HAART and also is a good model to study the
MDR strains of HIV-1 protease.

4.3 Conclusions
In summary, our results supports the hypotheses that the conformational
rigidity exhibited by the MDR769 HIV-1 protease hinders substrate binding and
therefore reduces catalysis. These studies have implications for the design of
potent competitive PIs against the MDR strains of HIV-1 protease as well as
enhancing the potency of maturation inhibitors (227) such as PA457 (92). In
addition, this work may have implications in studies related to viral replication
in

the

presence

and

absence

of

compensatory

mutations

in

the

substrate-cleavage sites. Based on our findings, we conclude that the
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conformational rigidity of the MDR769 HIV-1 protease flaps could be one of the
novel mechanisms for the multi-drug resistance nature of the MDR protease
and that new approaches are needed for further studies using models like the
MDR769 HIV-1 protease.
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CHAPTER 5: HIV-1 PROTEASE IC50 MEASUREMENTS WITH
LIBRARIES OF REDUCED CA/P2 PEPTIDES AND FDA
APPROVED INHIBITORS
5.1 Introduction
5.1.1 Selectivity and specificity of HIV-1 protease
It was reported that MDR HIV-1 proteases show reduced binding affinity to
FDA approved protease inhibitors, while they still keep a certain level of
enzymatic activity that is required for the viability of the virus itself (228-229).
As a result, the HIV-1 protease is highly specific for its natural cleavage site
peptides or their analogs (230-231). However, the selectivity of HIV-1 protease
is not obvious considering the wide variability of its substrate sequences.
Research has been performed to determine the best substrate for a particular
peptide sequence through kinetic measurements of hydrolysis of peptides with
single amino acids substitution at each position (232-234). Poorman et al
demonstrated that residues at positions P2, P1 and P2’ are critical for the
cleavage (235). However, later studies indicated that substrate recognition by
HIV-1 protease was achieved by shape of the substrate rather than the
sequence (205,236).

5.1.2 Reduced CA/p2 peptide library
CA/p2 cleavage site is the rate-limiting step in all the nine substrate
cleavage (237). HIV-1 protease can catalize the cleavage of as many as nine
different natural substrates with various catalytic efficiencies. CA/p2 cleavage
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site is cleaved by HIV-1 protease with the least efficiency compared to other
eight substrate peptides. As a result, we choose CA/p2 as our study model to
make a library of the reduced CA/p2 peptide analogs with substitution of one
amino acid only in each analog. In addition, the P4’ side Met was replaced by
NorLeucine to avoid the chemical synthetic obstacles. This library of reduced
CA/p2 analogs are contributed by our collaborator, Dr. Mark Spaller from
Dartmouth Medical School. The sequences of this reduced CA/p2 peptide
library is shown in Table 5.1. The comparison between the regular CA/p2
peptide and reduced CA/p2 peptide is shown in Figure 5.1. We measured the
IC50 of this library to both MDR769 HIV-1 protease and WT HIV-1 protease.
Similar studies were conducted by Altman et al on RT/RH analogs with
computational and thermodynamics techniques (238).

5.1.3 HIV-1 protease inhibitors
Similarly, the IC50 values of six FDA approved inhibitors against both
MDR769 HIV-1 protease and WT HIV-1 protease were measured to determine
the extent to which these inhibitors were resistant.
An HIV-1 protease inhibitor is one of the components of HAART. Currently,
there are ten FDA approved HIV-1 protease inhibitors on the market. Most of
these drugs contain a hydroxyethylene core and are peptidomimetic
competitive inhibitors against the HIV-1 protease by mimicking the natural
substrates (239-246) . Tipranavir, though, has a dihydropyrone ring as a
central scaffold rather than a peptidomimetic hydroxyethylene core (247).
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We have six of all the FDA approved HIV-1 protease inhibitors in our lab,
as shown in Figure 5.2. IC50 values of these inhibitors for both WT and
MDR769 HIV-1 protease were measured to determine the binding affinity.

5.1.4 Lopinaivr
Lopinavir, approved by FDA in 2000, is the only protease inhibitor that is
co-formulated with a low dose of ritonavir -- the combination is known as
Kaletra (Abbott).

In vitro assay showed IC50 of 6-17 nM range against

various stains (245). Although drug resistance is relatively less likely to
develop for lopinavir compared to other HIV-1 protease inhibitors (248),
resistance mutations are noticed, including 32I, 47A, and 46I, or L33F, I54V,
V82A, I84V, and L90M, or combinations among L76V, M46I, and V82A in the
protease, or A431V in gag (249-253). In addition, it was found that the
accumulation of mutations, including mutations of codons 82, 54, and 46,
during prior protease inhibitor treatment facilitates the emerging of lopinavir
resistant mutations (254).
We expect to have worse IC50 values of MDR769 HIV-1 protease against
both reduced CA/p2 analog library and the FDA approved inhibitors compared
to those of wild type HIV-1 protease. Based on this working hypothesis, it is
proposed that reduced CA/p2 analog library and the FDA approved inhibitors
bind to MDR769 HIV-1 protease with reduced affinity. In addition, the analysis
of the reduced CA/p2 analog library sequence and FDA approved inhibitor
structure, combined with the IC50 data, may lead to some hints in how to
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modify currently existing FDA approved HIV-1 protease to overcome the drug
resistance issue.
Table 5.1

CA/p2 reduced peptide librarya.

Reduced Peptide

P3

P2

P1

P1'

P2'

P3'

P4'

Original CA/p2

Arg

Val

Leu

Ala

Glu

Ala

Met

P1'F

Arg

Val

Leu

R

Phe

Glu

Ala

NorLeu

P2A

Arg

Ala

Leu

R

Phe

Glu

Ala

NorLeu

P2F

Arg

Phe

Leu

R

Phe

Glu

Ala

NorLeu

P1A

Arg

Val

Ala

R

Phe

Glu

Ala

NorLeu

P1F

Arg

Val

Phe

R

Phe

Glu

Ala

NorLeu

P2'A

Arg

Val

Leu

R

Phe

Ala

Ala

NorLeu

P2'F

Arg

Val

Leu

R

Phe

Phe

Ala

NorLeu

SP1

Arg

Val

Leu
Phe

Glu

Ala

NorLeu

SP2
a

The Sequnces of these peptides are listed from P3 site to P4’ site. The cleavage site

is between P1 and P1’. The first sequence represents the natural CA/p2 sequence
with a regular peptide bond between P1 and P1’. The capitalized letter “R” stands for
reduced peptide bond and makes the peptides uncleavable by active HIV-1 protease.
The mutagenesis is highlighted by red. The last two peptides SP1 and SP2 stand for
short peptide 1 and short peptide 2 respectively. They are the N and C terminal
cleavage products for natural CA/p2 peptide. In addition, the P4’ site is Methionine in
natural CA/p2 sequence and is mutated to NorLeu to avoid the chemical synthetic
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obstacles.

Fgire 5.1 Comparison of regular and reduced CA/p2 peptide bond. The
upper panel is the regular CA/p2 peptide and the lower panel is the reduced CA/p2
peptide. From the left to the right are P3, P2, P1, P1’, P2’, P3’, P4’ site respectively.
The peptide bond is reduced between P1 and P1’ site in the reduced CA/p2 peptide
analogs. The P4’ site is mutated from Methionine to NorLeucine to avoid chemical
synthesis difficulties. P2 to P2’ sites are subjected to mutations in order to explore the
influences of the binding affinity to HIV-1 protease introduced by different amino acid

103

residues.

Figure 5.2 Structure of FDA approved HIV-1 protease inhibitors. The
structures of six FDA approved inhibitors are shown in this panel. All of these inhibitor
contain a peptidomimetic hydroxyethylene core. Among these, lopinavir and ritonavir
demonstrate a symmetric P1/P1’ conformation, while others have different P1/P1’
functional groups.

5.2 Results
5.2.1 IC50 enzyme data with the reduced CA/p2 peptide analogs
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The IC50 values for the reduced CA/p2 peptide library are shown in Table
5.2.

Similar IC50 values are observed between MDR769 and WT HIV-1

protease against the library of reduced CA/p2 peptide analogs. In addition, the
SP1 (short peptide 1) and SP2 (short peptide 2), the cleavage products of
CA/p2, both fail to show feedback inhibition against either MDR HIV-1
protease or WT HIV-1 protease.
However, the reduced peptide P1’F with P1’ site Ala replaced by Phe
shows IC50 4.3 nM against MDR 769 HIV-1 protease, despite being slightly
higher than that of WT HIV-1 protease. This IC50 is even comparable to IC50
of some FDA approved HIV-1 protease inhibitors. P1’F with P1 Leu and P1’
Phe is a good combination, and we will explore other similar combinations
based on this.

Table 5.2

IC50 values of CA/p2 reduced peptide library against both

MDR and WT HIV-1 protease
Peptide

WT IC50 (nM)

MDR769 IC 50(nM)

P1'F

2.6

4.3 ± 0.02

P2A

78.17

74.1 ± 10.49

P1F

30.67

142 ± 4

P2'A

232.33

233.67 ± 3.21

P2F

1143.33

770.33 ± 62.96

P2'F

1009.67

1263.33 ±106.93
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P1A

4873.33

5020 ± 434.86

SP 1

100000

103866.7 ± 7145.16

SP 2

N/A

664333.3± 72885.5

5.2.2 IC 50 enzyme data with the six FDA approved HIV-1 protease
inhibitors
The IC50 values of six FDA approved protease inhibitors, amprenavir,
indinavir, lopinaivr, ritonavir, nelfinavir, and saquinavir, against both MDR 769
and WT HIV-1 protease are given in Table 5.3. Analysis of the data shows
significant drug resistance of MDR HIV-1 protease against all protease
inhibitors except for lopinavir, compared to those of WT HIV-1 protease. The
IC50 increase of lopinavir is only 4-folds from WT to MDR HIV-1 protease. As
a result, lopinavir is a good starting point to modify the existing FDA approved
HIV-1 protease inhibitors in order to restore the inhibitor binding affinity without
dramatically altering the ADME (absorption, distribution, metabolism, and
elimination) and toxicity of the potential drug candidates.

Table 5.3

IC50 values of FDA approved inhibitors against both MDR and

WT HIV-1 protease
Inhibitor

WT (nM)

MDR769 (nM)

IC50 increase

106

Amprenavir

0.4763 ±0.031

5.94 ±0.145

12.47

Indinavir

2.67 ±0.832

142.3 ±23.46

53.29

Lopinavir

1.237 ±0.139

5.39 ±0.225

4.357

Ritonavir

0.443 ±0.007

56.17 ±5.34

126.79

Nelfinavir

2.18 ±0.1

104 ±1.732

47.71

Saquinavir

0.514 ±0.00436

311.3 ±15.822

605.64

5.3 Discussion
5.3.1 Substrate cleaveage efficiency of WT and MDR HIV-1
proteases
The chemical cleavage step is disrupted by the mutations in MDR769
HIV-1 protease. Two independent steps are required for the process of HIV-1
protease substrates. The first step is the physical binding of the substrates to
the HIV-1 protease. The second step is the chemical cleavage of the
substrates, which is executed by the residues Asp 25 and Asp125. Our
enzyme assay shows similar IC50 values of MDR769 and WT HIV-1 protease
against the library of reduced CA/p2 peptide analogs. It indicates that the
binding affinity of this library is similar regardless of the MDR or WT HIV-1
protease. Meanwhile, other studies indicate certain degree loss of catalytic
acitivity of MDR HIV-1 protease, compared to that of WT HIV-1 protease, in
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cleaving the substrate peptides. As a result, it is expected that the chemical
cleavage step rather than the physical binding step of the substrate peptide is
disrupted by the drug resistance rendering mutations. This chemical cleavage
disruption may result from the expanded active site cavity of the MDR HIV-1
protease. Due to the extra space in the active site cavity allowing relatively free
movement of the substrate peptides, the substrate peptides are thought to be
floating in the active site cavity. This makes the substrate peptide cleavage site
less accessible to the two “active residues” Asp 25 and Asp 125.

5.3.2 CA/p2 P1’F reduced peptide shows highest IC50 against both
WT and MDR HIV-1 protease
It was surprising to learn that the reduced peptide P1’F inhibits the WT and
MDR HIV-1 protease with IC50 values comparable to those of the FDA
approved HIV-1 protease inhibitors. Despite the fact that MDR HIV-1 protease
was slightly resistant to reduced peptide P1’F, the absolute value of the IC50
indicated that reduced peptide P1’F is a potential drug candidate with P1/P1’
combination Leu and Phe. Other similar combinations of P1 and P1’ sites are
explored to optimize the inhibitory activity of the reduced CA/p2 peptide
analog. In addition, to further comfirm the importance of the P1/P1’
combination, a shorter peptide library, ranging from P2 to P2’ sites rather than
P3 to P4’, will be synthesized and tested against WT and MDR HIV-1
protease.

5.3.3 P1/P1’ site symmetry of lopinaivr may contribute to the
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enhanced drug efficacy
Lopinavir shows a four-fold drug resistance by MDR HIV-1 protease.
Further analysis of lopinavir and other protease inhibitors reveals a unique
characteristic of lopinavir -- the symmetric P1 and P1’ sites. Ritonavir, similar
to lopinavir, shows a symmetric P1/P1’ sites, but does not demonstrate similar
pattern of drug resistance. However, it is possible that the bulky volume of
ritonavir makes it less potent against MDR HIV-1 protease. The symmetry of
P1 and P1’ site of lopinavir is under further investigation to understand the
potential application of the symmetric sidechain concept to HIV-1 protease
structure based drug design, given the symmetric nature of the enzyme. In
addition, lopinavir and ritonavir will be cocrystallized with MDR HIV-1 protease
to understand in details the mechanism of different patterns of drug resistance.

5.3.4 Implication of the discrepancy between the library of reduced
CA/p2 peptide analogs and inhibitor IC50 values
The IC50 values of the library of reduced CA/p2 peptide analogs
surprisingly fail to show the different binding affinity of the WT and MDR HIV-1
protease to the substrates. However, the inhibitor enzymatic studies give the
expected different binding affinities of these inhibitors to WT and MDR HIV-1
protease, although the difference varies in different inhibitors. The comparison
between the reduced CA/p2 analogs and FDA approved HIV-1 protease
inhibitors reveals the following differences:
1. The reduced CA/p2 peptides comprise of seven amino acid residues,
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while the inhibitor range from P2 to P’ sites only, equal to four
amino acid residues in length
2. There is one hydroxyl group between the P1 and P1’ sites of the
protease inhibitor mimicking the crystallographic water critical in
substrate cleavage in the HIV-1 prtease substrate complex, while
no such corresponding functional group is observed in the reduced
CA/p2 peptide analogs
3. The difference in the environment of the hydroxyethylene carbon
atom may make a difference in binding affinity. The inhibitors have
an R1-CH2-CH(OH)-CH2-R2 structure whereas the reduced
CA/p2 analogs have an R1-CH2-CH2-NH-R2.
Consequently, there are three possible ways to modify the FDA approved
inhibitors to overcome the drug resistance issue by restoring the binding
affinity to MDR HIV-1 protease. First, expand the existing protease inhibitors.
The extent to which the expansion can reach needs to be carefully calibered.
On one hand, if the volume is not big enough, the binding affinity is not
increased enough to achieve the desirable results. One the other hand, an
over-expanded inhibitor may lose its target specificity and lead to intolerable
toxicity despite the high activity. In addition, the bioavlaibity may be
unfavorable with large inhibitors. Second, the hydroxyl group between P1 and
P1’ sites may be removed or substituted by other functional groups to generate
the modified inhibitors with better IC50 values and higher binding affinity to the
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MDR HIV-1 protease. Third, one of the carbon atoms flanking the hydroxyl
group between P1 and P1’ site may be substituted by a nitrogen atom. Which
carbon atom to be replaced cannot be determined based on current functional
studies. Further experiment with either of these two carbons replaced by
nitrogen atom separately will be helpful in determining the significance of each
flanking carbon atoms to the ligand binding affinity to the MDR HIV-1 protease.
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CHAPTER 6: CRYSTAL STRUCTURE OF THE EXTRA-CELLULAR
DOMAIN OF HUMAN MYELIN PROTEIN ZERO
6.1 Introduction
6.1.1 Function of the myelin protein zero
Myelin protein zero (MPZ) is the causative gene for CMT1B, although it
is much less common than CMT1A, accounting for less than five percent of all
CMT1 cases (142,151-152).
Myelin

protein

zero

(MPZ),

associated

with

CMT1B,

is

a

transmembrane protein of 219 amino acid residues. Human MPZ consists of
three

domains:

first,

125

residues

constitute

the

glycosylated

immunoglobulin-like extracellular domain; second, 27 residues span the
membrane; and third, 67 residues represent the highly basic intracellular
domain (160-161). MPZ, a homophilic adhesion molecule (162-164), is a
member of the immunoglobulin super-family (165) and is essential for normal
myelin structure and function.

6.1.2 Structure of the extracellular domain of human MPZ
We report the crystal structure of the extracellular domain of human MPZ
(hP0ex) fused with the maltose binding protein (MBP) at resolution 2.1 Å.
Despite the fact that the crystal structure of rat MPZ extracellular domain
(rP0ex) is available (166), the crystal structure of the human counterpart is
indispensible considering several critical amino acid residue variations
between the two homologues . There are three sequence differences at amino
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acid residues 10, 16 and 77. Residue 10 is a clinically important site where a
mutation may lead to phenotypic change. MPZ residues 16 and 77 are at the
four-fold interface and head-to-head interface according to the packing of the
rat P0ex model. Consequently, the crystal structure of the human P0ex is
necessary to understand the mechanism of CMT disease.

6.1.3 Functional studies of clinically important mutants of MPZ
In addition, based on the crystal structure of hP0ex, we investigate the
molecular mechanism of pathogenesis of MPZ mutants H10P, R69C, R69H,
T95M, and H52R. First, Li et al demonstrated that mutant H10P, causes late
onset CMT1B and presents severe length-dependent axonal loss without
segmental demyelination.

Material either in the inner wraps of myelin and/or

periaxonal space coexisted with the accumulated MPZ. In addition, the
molecular organization of the axolemma (Mauthner sheath or plasma
membrane of the axon) showed abnormalities (255). Second, R69C mutations
caused an early onset CMT1B (256-258). Further investigation showed
regions of uncompacted myelin, one of the two types of pathology as seen in
other early onset CMT1B (259-260). Onion bulb formation, thinly myelinated
axons (261), and amyelinated fibers were also noticed in this mutant. Third,
T95M, a mutation leading to later onset CMT1B, did not interrupt the normal
intracellular traffic of MPZ and affected the intercellular adhesion moderately.
However, this mutation interfered with the glycosylation of MPZ, which is
important for MPZ function. Fourth, mutation H52R, unlike other early onset
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CMT1B causing mutations, showed no adverse affects on the intracellular
traffic of MPZ. The MPZ with mutation H52R could reach the cell surface but it
significantly reduced the intercellular adhesion (262).

6.1.4 Amyloidosis and CMT1B
Recent studies have linked amyloidosis to CMT1B caused by certain
mutations such as T95M (263). In amyloidosis, amyloid fibrils, derived from
naturally soluble protein or protein fragments, are insoluble and accumulate in
a variety of organs and tissues (264-267). The orginal naturally soluble
proteins are unrelated and may be rich in β sheet, α helix, or both α helices
and β sheets. They may be rigid globular proteins or natively unfolded proteins
(268-274). However, the amyloid fibrils contain a common core structure of
cross folded β-sheets, consisting of continous β sheets with the β strands
running perpendicular to the long axis of the fibrils (275). Immunoglobulin light
chain amyloidosis (AL amyloidosis), associated with a plasma-cell dysfunction
(276), is the most common amyloidosis in the US (277).The immuolglobulin
light chains, light chains and heavy chains, or fragments of heavy chains
cannot be broken down to constituent amino acids due to the misfolding (278).
The light chains assemble into protofibril and then into amyloid fibril in the form
of an amyloid fribril subunit (279). The light chain of immunoglobulin contains
two immulogolulin fold structures, while the extra cellular domain of human
MPZ has a single immunoglobulin fold structure. It is possible that the X-ray
diffraction studies will reveal an amyloid structure of the hP0ex mutants that
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causes CMT1B. Further studies of the β-pleated sheet binding to Congo red
with its tinctorial properties of green birefringence under polarized light may
provide an alternative way to study the hP0ex mutants besides the the unique
X-ray

diffraction

pattern.

Amyloid

protein

diffraction

patterns

show

characteristic perpendicular reflections along the meridional direcction at 4.7 Å
and along the equatorial direction at 10 Å (280).

6.2 RESULTS
6.2.1 Crystal structure of the MBP hP0ex fusion
hP0ex fused with MBP crystallized in space group P21. The
crystallographic parameters are shown in Table 6.1 with the final structure
refined to 2.1 Å resolution. The electron density maps, contoured at 2 sigma, of
the maltose in the MBP and the intra-molecular disulfide bond in the hP0ex are
shown in Figure 6.2. Two fusion proteins are included in one crystallographic
asymmetric unit, with one maltose ligand in each MBP molecule (Fig. 6.1). The
MBP adopts the “closed” conformation in the presence of the maltose
molecule. The connecting region (22 amino acid residues, part of the
pMal™-p2X vector) between the C-terminus of MBP and the N-terminus of
hP0ex was difficult to trace and therefore was omitted due to the poor electron
density of these residues. As a result, one fusion protein molecule was treated
as two independent chains in the deposited PDB file. Two intact hP0ex (from
residue 1 to residue 121) were present in one crystallographic asymmetric unit.
The last four residues of the C-terminus, 122 - 125 (Pro, Thr, Arg, and Tyr),
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were disordered due to flexibility and therefore omitted. The major interface in
the crystal was between two MBP interfaces involving residues Asp 120 (Asn
205, Lys 202 of molecule two), Lys 239 (Asn201 of molecule two), Asp 314
(Lys 142 of molecule two), Pro 315 (Gly 143 of molecule two), and Arg 316
(Ala141 of molecule two). hP0ex Arg 77 only contacted MBP via Glu 359
because of the flexible connecting region; hence, no significant obstruction of
the quaternary structure was induced by the close proximity of the large MBP
domain.

Table 6.1 Data Collection and Crystallographic Refinement Statistics
Data Collection
Beam Line
Wavelength (Å)
Space group
Cell dimension (Å) a, b, c
α, β, γ
Resolution (Å)
R merge (%)a
I/σ(I)
Redundancy
Completeness (%)
Unique reflectionc
Refinement
Resolution range (Å)
R work (%)d
R free (%)e
No. of protein residue
No. of water molecule
B factor
Whole molecules
Side chain (include water)
Main chain

APS (LS-CAT 21)
0.9779
P2(1)
a=61.91
b=54.77
c=145.85
α=90.00
β=98.49
γ=90.00
30.00-2.00
8.7/53.9b
21.6/4.3
3.5/3.4
99.9/100
77053
19.96-2.1
19.2
25.9
976
507
28.995
30.311
27.543
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Ligand (Maltose E/F)
Solvent
RMSD
Bond length
Bond angle
Ramachandran Plot
Favorable (%)
Additional (%)
Generous (%)
Forbidden (%)
PDB accession ID

18.109/17.607
36.411
0.012
1.597
89.3
9.1
1.7
0
3OAI

a

Rmerge= ΣhklΣi|I(hkl)i-{I(hkl)|/ ΣhklΣiI(hkl)i , where I(hkl)i is the intensity of an

observation and I(hkl) is the mean value for its unique reflection. Summations cover
all reflections.
b

The values after the hyphens indicate the highest resolution shell.

c

Nobs/Nunique.

d

Rwork= Σhkl|F(hkl)o- {F(hk|/ΣhklF(hkl)o

e

R free was calculated same way as R working, but with the reflections excluded from

refinement. The R free set was chosen using default parameters in Refmac 5

6.2.2 Crystal Structure of hP0ex
It was predicted and found that hP0ex domain shows significant similarity to
the members of the immunoglobulin family (281), specifically, a v-type
immunoglobulin fold (282). The structure of rP0ex, a homolog of hP0ex, has
also been assigned to the immunoglobulin superfamily (166). Our crystal
structure further confirmed this finding (Figure 6.1 and Figure 6.3). The
structure consists of nine antiparallel β strands forming a barrel-like shape.
However, as with other immunoglobulin superfamily members, the hydrogen
bonds do not go around the barrel, the structure is physically a β-sandwich
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comprised of two distinct β-plated sheets (283). Strands D, E, B, and A make
up one β sheet, while strands D, F, C, C’, C’’ constitute the other β sheet. In
spite of the proximity between strands A and B, the entire length of strand A
forms hydrogen bonds with strand G. A similar conformation is seen in
molecules CD2 (284) and CD4 with a truncated strand A (285-286). In some
other immunoglobulin superfamily members such as CD8 (287) and VCAM-1
(288), the first half of the strand A forms hydrogen bonds with the strand B,
while the second half forms hydrogen bonds to strand G. Strands B, C, E, F,
and G present a rigid hydrophobic core characteristic of immunoglobulin
variable domains. In addition, one conserved disulfide bond is also found
bridging strands B and F.
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Figure 6.1. Crystal structure of the fusion protein MBP- hP0ex. In green
color is the closed-form of MBP with a maltose molecule. In blue color is the hP0ex
and the linker connecting MBP and hP0ex is presented by dotted line due to
disordered structure.
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Figure 6.2 The electron density map of maltose and disulfide bond at 2.0
sigma. Upper panel shows the MBP with maltose molecule. The lower panel shows
the intra-molecular disulfide bond in hP0ex. The electron density map is rendered by
a blue mesh.
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6.2.3 The overall structures of hP0ex and rP0ex are similar
Although three residues differ between hP0ex and rP0ex (H10Y, R16Q,
and R77S), the overall structures of hP0ex and rP0ex are quite similar (Figure
6.4). These mutations are located on the surface of the hP0ex, making hP0ex
more basic compared to rP0ex. The overall more basic characteristic of hP0ex
may be important in understanding the differences between human and rat
Schwann cell functions. The two crystal structures also differ at the FG loop
which is continuous in hP0ex but broken in rP0ex due to four disordered
residues (Pro103, Pro104, Asp105, and Ile106, Figure 6.4).
Secondary structure analysis based on the hP0ex and rP0ex structures
rendered with the program PyMOL, revealed almost identical secondary
structure compositions. Both hP0ex and rP0ex represent a typical v-type
immunoglobulin fold (282). The difference between the two structures is that
some β strands in the hP0ex are missing. The loss of some secondary
structure elements in hP0ex makes it relatively more flexible. For instance,
strands A’ and B’ are not seen and helix 1 (residues 76 to 78) is missing in
hP0ex . The absence of helix 1 in hP0ex may be partially due to the change of
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Figure 6.3.

hP0ex forms a v-type immunoglobulin fold. The secondary

structure elements are highlighted by different colors. β strands are shown in blue and
the helices are in brown color and loops are in black. The intra-molecular disulfide
bond is shown in dark yellow.
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Figure 6.4.

Comparison between hP0ex (blue) and rP0ex (purple and

black dots). The overall structures are highly conserved between the two species,
considering the similarity in the amino acid sequence. However, the hP0ex structure
contains the amino acid sequences that are difficult to track due to the broken electron
density map for rP0ex.
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codon 77 from Arg in hP0ex to Ser in rP0ex. The other two variations between
hP0ex and rP0ex, H10Y and R16Q, appear not to alter the secondary
structure

6.2.4 Some regions in hP0ex show high flexibility relative to rP0ex
Superposition based on Cα of the hP0ex and rP0ex structure shows
high root mean square deviations (RMSD) in some regions. RMSD is more
than 1 Å for both main chain and side chain in the following regions: the
N-terminus (residues 1 and 2), loop BC (residues from 25 to 32), loop C’’D
(residues 62, 63 and 64), both ends of the disordered loop in rP0ex (residues
102 and 107). RSMD analysis shows abnormally high RMSD regions (side
chain only) in the following: N-terminus (residue 4), Strand A ( residues 7, 8
and 10), loop AB ( residue14), loop BC ( residues 23,24, and 33), loop CC’
( residues 45 and 46), strand C’ (residues 48 and 49), loop C’C’’ (residues 54
and 55), strand C’’ (residues57, 58 and 60), loop C’’D (residues 61, 65, 67 and
70), loop DE (residues 78, 79 and 83), the broken ends in rP0ex (residues 101
and 109), strand G ( residue112), and C-terminus (residue119). Areas
surrounding the three variation sites show high RMSD values (Figure 6.5).
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Figure 6.5 The RMSD digram based on the superposition of hP0ex and
rP0ex on the Cα
α. The X axis is the residue number and the Y axis the RMSD value.
The series 1 (blue) represents the main chain RMSD and the series 2 (purple) is the
RMSD of the side chain. The corresponding missing residues in hP0ex from residues
103 to 106 are omitted in the comparison. In addition, to facilitate the comparison,
residues after 102 are renumbered.

6.2.5 The ß-strand A in hP0ex is relatively shorter than the matching
ß-strand in rP0ex
Although the core of the immunoglobulin fold between hP0ex and rP0ex,
consisting of strands B, C, E, F, and G, is highly conserved, the most significant
difference among β strands is located in strand A. In hP0ex, strand A is
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relatively shorter than that in rP0ex, forming hydrogen bonds only with strand
G. In contrast, strand A in rP0ex is divided into two small strands, A and A’. In
rP0ex, strand A forms hydrogen bonds with the strand B, and strand A’ forms
hydrogen bonds with strand G (Figure 6.4), as seen in CD8 (287) and VCAM-1
(288). As a result, the stand A in hP0ex is relatively flexible compared with that
in rP0ex. Subsequent mutations on strand A, such as H10P, may further
destabilize strand A in hP0ex.

6.2.6 Surface area of hP0ex is larger than the surface area of rP0ex
The surface area in hP0ex (with 552 surface atoms from 115 residues)
is increased by 155.9 Å2 compared to that of rP0ex (with 561 surface atoms
from 115 residues). The individual amino acid residue surface areas are shown
in Figures 6.6 and 6.7. The surface areas of residues 1, 2, 7, 8, 16, 24, 32, 57,
65, 77, 101, and 119 are increased each by at least 20 Å2, while surface areas
of residues 10, 62, 64, 97, 102, and 107 are each decreased by more than 20
Å2. The surface area changes at residues 10, 16, and 77 are due to the
sequence variation between the human and rat protein. The surface area
changes at residues 1, 2, 101, 102, 107, and 119 may be caused by the
flexibility of N- and C- termini and the broken ends within rP0ex. The increased
extracellular surface area of hP0ex may strengthen the interactions among
hP0ex molecules on the surface of Schwann cells, leading to higher affinity
between homophilic molecules.
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Figure 6.6 The surface area of individual amino acid residues in both
hP0ex and rP0ex. The X axis is the amino acid residue number and the Y axis is
the surface area of individual amino acid residues in square Angstroms. The blue
series represents the surface area of hP0ex residues and the purple series represents
the surface area of rP0ex amino acid residues. The overall surface area distribution is
similar between hP0ex and rP0ex, however certain amino acid residues show large
surface area differences that may affect the overall stability of the molecules and
inter-molecule interactions. The corresponding missing residues in hP0ex from
residues 103 to 106 are omitted in the comparison. In addition, to facilitate the
comparison, residues after 102 are renumbered.
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Figure 6.7. The difference of surface area of individual amino acid
residues between hP0ex and rP0ex. The X axis is the amino acid residue
number and the Y axis is the surface area difference of individual amino acid residues.
The overall surface area distribution is simlar between hP0ex and rP0ex, however,
certain amino acid residues show large surface area differences that may affect the
overall stability of the molecules and inter-molecule interactions. The corresponding
missing residues in hP0ex from residues 103 to 106 are omitted in the comparison. In
addition, to facilitate the comparison, residues after 102 are renumbered.

6.3 Discussion
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6.3.1 hP0ex tetramer assembly based on the rP0ex tetramer
An hP0ex tetramer was assembled to investigate the hP0ex homophilic
adhesion capacity based on the rP0ex tetramer conformation. Although the
hP0ex tetramer does not exist in the crystals, due to steric hindrance from the
MBP chain, the hP0ex tetramer is plausible both from the aspect of proposed
hP0ex homophilic adhesion capacity and from the crystal structure of rP0ex
showing a tetramer conformation.
The rP0ex tetramer is generated through symmetry operations based on
the rat tetramer model (166). Four individual hP0ex molecules are superposed
onto the rP0ex tetramer. The four resultant hP0ex molecules from the
superposition are combined to give a hypothetical hP0ex tetramer (Figure 6.8).
The hP0ex and rP0ex tetramers are highly conserved, which is essentially
determined by the similarity between hP0ex and rP0ex monomer molecules.
However, there are three key differences between the human and rat
tetramer model. First, in the hP0ex tetramers, the interaction between loop BC
of one molecule and loop C’’D and EF of the next molecule in the four-fold
interface as defined by Shapiro et al.(166) is stronger than in the rP0ex
tetramers. In the rP0ex tetramer, a stacking interaction is formed between Trp
24 in loop BC (of one monomer) and His 86 in loop EF (of the adjacent rP0ex
monomer) due to the relatively long distance. However, in the modeled hP0ex
tetramer the side chains of Trp 24 in loop BC (of one monomer) and His 86 in
loop EF (of the adjacent monomer) are too close to one another and they
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appear to clash. Second, the N-terminus of hP0ex is more flexible and forms a
loop, while the N-terminus of rP0ex is more organized in the form of a β strand.
As a result, the hP0ex N-terminus of one molecule is bent toward the loop EF
of the next hP0ex, forming two extra hydrogen bonds between Ile 1 and Asn 87.
In contrast, the N-terminus of rP0ex forms hydrogen bonds with strand B within
the same molecule. Third, the C-termini of hP0ex are thought to form anchors
by which the hP0ex tetramers are attached to the Schwann cell membrane. It
is anticipated that the C-termini point away from the tetramer structure and
toward the membrane. However, the structure we solved does not support the
above model. The four C-termini from the four monomers curve back into the
donut-like hole within the tetramer. This curving of the C-terminus may be
explained by the lack of membrane interaction and molecular flexibility.

6.3.2 Five clinically important mutations of hP0ex
Five clinically important mutations on hP0ex are under investigation,
specifically, H10P, R69C, R69H, T95M, and H52R. These mutations are
dispersed throughout the entire hP0ex molecule, as shown in Figure 6.9.
Mutation H10P is located on strand A and mutations R69C and R69H are
located on loop C’’D. Mutation T95M is on strand F and mutation H52R is on
stand C’. All these mutations lead to early or late onset neuro-degenerative
disease.
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Figure 6.8. Superposition of hP0ex tetramer (blue) and rP0ex tetramer
(purple). A tetramer does not exist in the hP0ex crystal structure. However, a
tetramer has been identified as the “biological structure” in the rP0ex cystal. The same
crystallographic symmetry operation is performed to generate the tetramer structure
of hP0ex. The two tetramer structures of hP0ex and rP0ex then are superposed
based on the Cα atoms. As shown in this figure, the two tetramer structures overlay
each other well. However, further investigation reveals that some steric conflicts exist
among the hP0ex monomers on the inter-molecule surface.
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Figure 6.9 hP0ex monomer with H10P, R69C, T95M, and H52R mutations.
The clinically important mutations are shown by a stick model. The intra-disulfide
bond is shown in dark yellow color.
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The five clinically important mutations are highlighted in the hP0ex
tetramer to investigate the structural influences imposed by these mutations on
hP0ex function (Figure. 6.10). While mutation H10P is not on any
inter-molecular interface within or between the hP0ex tetramers, it might
disrupt the hP0ex monomer structure. In the H10P mutant, no obvious
interruption in the tetramer structure is predicted. However, as the modeling
prediction of the H10P structure indicates, the introduction of mutation H10P
may disrupt the intra-molecular disulfide bond and thus lead to structural
instability of the hP0ex monomers (unpublished results). The disruption of the
hP0ex monomer structure, in turn, may affect the tetramer formation and its
function. A discussion of the other four clinically important mutations follows in
the next paragraph.
Mutations R69C and R69H may reduce the homophilic adhesion
capacity of hP0ex through disruption or weakening of hP0ex tetramers. These
mutations are located on loop C’’D, which is an important inter-molecular
interface for tethering four hP0ex monomers together in the hP0ex tetramer.
The mutation from Arg to either Cys or His shortens the side chain of the
residue 69 and may result in weakened interaction between the loop C’’D from
one monomer and the loop BC from the adjacent monomer. Mutations T95M
and H52R are on the outer surface of the hP0ex tetramer and might influence
the hP0ex function by disrupting inter-tetramer interactions.
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Figure 6.10. Important mutations shown in the hP0ex tetramer. The ribbons
in different color are individual hP0ex monomers. Mutations are shown by stick model.
The anaylsis of the structural influences introduced by the mutations is limited if the
analysis is confined to the hP0ex monomers. Visualization of the mutations in the
hP0ex tetramer takes into account the possible intra-monomer, inter-monomer, and
inter-tertramer structural disruptions induced by these mutations, thus more
comprehensive in the analysis.
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6.3.3 Prediction of the structure of H10P hP0ex
The histidine residue at position 10 of the human MPZ coding sequence
is one of three amino acids that differ between the human and rat MPZ
extracellular domains, and is one of 8 amino acids located within a ß-strand in
which the root mean square deviation between the human and rat proteins is
greater than 1 Å. Mutation of this residue to proline (H10P) causes a late onset
form of CMT1B in several large families (155). Nerve conduction velocities in
affected individuals are preserved, suggesting that myelin can functional
normally. The peripheral nerve pathology associated with the H10P mutation,
however, demonstrates accumulation of proteinaceous material between
Schwann cells and axons, as well as focal areas of tomaculous-like myelin
disruption (functional disturbance or pathological change), suggesting
abnormal myelin breakdown and/or turnover.
In order to investigate a structural contribution to the H10P phenotype,
we have used the crystal structure of the hMPZex to predict the hMPZex H10P
structure by performing molecular modeling. The result of the simulation
demonstrates several important changes in the MPZ structure caused by the
H10P mutation. Because of the proline at residue 10, the N-terminus now
forms an A’ ß-strand similar to that in the rat MPZ which gives rise to an
anti-parallel ß-sheet with the downstream segment of the B strand pulling the
A’ strand toward the N-terminus and away from the F strand. As a
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consequence, the distance between Cys21 and Cys98, located on the B and F
strands, is increased to 3.7 Å, thus the disulfide bond between these two
residues can no longer form. Absence of the disulfide bond between the two
ß-sheets, a highly conserved element of Ig domain structure, probably causes
the H10P mutant to be less stable than its wild type counterpart. In addition,
the two cysteine residues could interact with free cysteines from other proteins,
leading to the formation of disulfide-linked MPZ complexes. The substitution of
proline at position 10 also directly alters the protein backbone by producing a
“kink” at that location. A comparison of the wild type and H10P mutant forms of
hMPZex is shown in Figure 6.11.
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Figure 6.11. Structural comparison of the wild type and H10P mutant
forms of MPZex. The left panel shows the superposition of the wild type (sky blue)
and predicted H10P-MPZex (gold). The right panel more closely focuses on the
disulfide bond region, showing the broken disulfide bond in H10P-MPZex. The overall
structure of wild type MPZex and the H10P-MPZex are similar. However, the broken
disulfur bond indicates the possibility of inter-meluclar disulfur bonds, which may be
the reason of oligomerization of the H10P-MPZex.
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6.3.4 Crystallization of proteins fused to the maltose binding
protein
According to a recent report from the Joint Center for Structural Genomics
(http://www.jcsg.org), among all the proteins that are expressed, only 9.8%
could be crystallized with favorable size and quality for X-ray screening. 74%
of these crystals diffract X-ray for further data collection. Furthermore, only
50% of these crystals with diffraction data can be solved. As a result, the most
serious obstacle for crystallographers is to grow high quality protein crystals.
Several different methods were developed recently to facilitate the
crystallization of proteins that were previous refractory to crystallization (289).
These methods include optimization of target constructs, noncovalent
crystallization

chaperones,

removal of

post-translational modifications,

stabilization of protein targets, surface-entropy reduction (SER), improvement
of crystal quality, and the use of fusion proteins for crystallization.
Different carrier fusion proteins have be used, a tag protein fused with the
target protein, to facilitate protein crystallization, such as maltose binding
protein (MBP), thioredoxin (TRX) (290-291), glutathione-S-transferase (GST)
(292-295) and lysozyme (296-299). Usually the presence of the tag proteion
helps increasing both the expression and solubility of the target protein
(300-302), in addition to the simplification of protocol of target protein
purification if the tag proteins are affinity tags (303-304).
Among all the potential tag proteins, the protein with highest success rate
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is the maltose binding protein. It is usually added on the N-terminus of the
target protein and can act as a chaperone-like protein to facilitate the proper
folding of the targets (305-306). The protein crystals obtained through the
fusion of MBP are listed in Table 6.2.
However, it is not uncommon that the target proteins are still refractory to
crystallization despite of the presence of MBP to increase the expression and
solubility (307-310). In these cases, we may introduce some mutations on
MBP itself in order to achieve the goal of maximal surface entropy reductions
(SER) (311-313).
However, the addition of the MBP tag to the target proteins may itself
cause some undesirable outcomes. The MBP itself is more than 300 amino
acid residues, thus limit the size of target proteins that are suitable for E. coli
expression system. The presence of MBP on the N-terminus of the target
protein may disrupt the native structure of the target protein, especially when
the N-terminus of the target protein is functionally important and is involved in
certain structural interactions. In addition, the linker region connecting the MBP
and the target proteins may introduce significant structural heterogeneity,
compromising the quality of the crystals. To partially solve this problem, the
most effective method is to minimize the length of the linker region.

139

Table 6.2. Crystal structures with maltose binding protein as the large
affinity tags.

Addapted from Moon et. al.(314)

Target protein

Size (AA)

Resolution

Linker sequence

(A ° )
HBS antigen(315)

14

2.7-2.9

GS

IAP(316)

22

1.75-1.86

AAA

MutS (C-term)(317)

34

2.0

HM

MATa(187)

50

2.1-2.3

AAAAA

Huntingtin

66

3.5-3.7

AAA

TIM40/MIA40(319)

82

3.0

SSSVPGRGSIEGRPEF

gp21(186)

88

2.5

AAA

Monobody YSX1(320)

91

2.0

GSSGSS

Monobody YS1(320)

93

1.8

GSS

IPS1 CARD domain(321)

93

2.1

SAMA

CRFR1 ECD(322)

96

1.96-3.4

AAAEF

ZP3 (ZP-N domain)(323)

102

2.3-3.1

AAA

L30(324)

103

2.31

SSSVPGRGSIEGRA

gp21(325)

108

-

AAA

108

1.9

SSSNNNNNNNNNN

115

2.3

AAAEF

(N-term)(318)

designed helical
protein(326)
SarR(185)
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Argonaute2 PAZ (327)

136

2.8

AAAEF

PTH1R ECD(328)

174

1.95

AAAEF

256

2.4

N/Ab

2OST(330)

298

2.65

AAA

RACK1A(331)

324

2.4

AAA

NEDD8(332)

431

2.8

AAA

hP0exc

121

2.1

AAA

CD38(329)

a

All target proteins listed in this table are fused C-terminal to the carrier protein,

unless otherwise stated.
b

Information not available.

c

The structure discussed in this dissertation.

6.3.5 Amyloidosis and CMT1B
Crystallization attempts, including the in-house and high-throughput
screens, have been performed to obtain diffration quality crystals of mutants of
hP0ex, such as H10P and R69H. However, no crystals were obtained despite
the thorough screening. The fact that mutants are refractory to crystallization
may indicate that a single mutation introduces a major structural disturbance
into the fusion protein. The target hP0ex mutants may be disoriented in the
crystal lattice established by the malose binding protein. Another possibility is
that the hP0ex mutants form amyloids depite the presence of maltose binding
protein. If the second hypothesis is correct, the protein sample is expected to
show characteristic tinctorial properties of green birefringence under polarized
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light after it is stained with the dye Congo red. Futher experiments might
include expression and purification of hP0ex mutant without maltose binding
protein to enhance the possibility of amyloid formation compared to the protein
fused with maltose binding protein.
Theoretically, it is possible that amyloid formation is deferred or even
blocked if a certain small molecule binds to the altered structure of hP0ex
without introducing any major structural or functional changes, In silico
screening is currently performed to identify small molecules with high binding
affinity to the hP0ex mutants. The identified molecules could be evaluated for
efficacy in a transgenic mouse model with a MPZ knockout. These molecules
are potential drug candidates to alleviate the signs and symptoms, and/or
blocking the progression of CMT1B disease.
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CHAPTER 7: SUMMARY AND FUTURE DIRECTIONS
7.1 Summary
7.1.1 Summary of the MDR HIV-1 protease project
•

No significant conformational changes are observed at the point of
additional mutation in each of the corresponding MDR 769 HIV-1
protease variants.

•

The proline 81 switch in the MDR769 I10V mutant HIV-1 protease leads
to signifant conformational changes of the active site cavity.

•

The Phe82 side chain in the MDR769 A82F mutant reveals the
flipped-out conformation.

•

The hydroxyl group on the side chain of residue 82 points away from the
active site cavity in A82S while it is pointing towards residues Leu23.

•

The wild type and A82F mutant protease dimers display a larger surface
area at the dimer interface.

•

Molecular dynamics simulations show two-fold and three-fold opening
of the flaps in the MDR and wild type HIV-1 proteases.

•

The substrate (Gag-Capsid) is less stable in the expanded active site
cavity of the MDR769HIV-1 protease.

•

The conformationa of the substrate (Gag-Capsid) is changed during the
MD simulations.

•

The substrate cleavage site in MDR protease-substrate complex fails to
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align between the catalytic aspartic acid residues after the MD
simulations.
•

No significant differences are noticed for the IC50 values of the reduced
CA/p2 peptide library against MDR and WT HIV-1 protease.

•

Reduced peptide P1’F shows IC50 value against MDR HIV-1 protease
comparable to that of FDA approved HIV-1 protease inhibitors.

•

All six FDA approved inhibitors (amprenavir, indinavir, lopinaivr,
ritonavir, nelfinavir and saquinavir) are resisted by MDR HIV-1
protease.

•

Lopinavir is the least resisted HIV-1 protease inhibitor among the six
inhibitors.

7.1.2 Summary of the human myelin protein zero project
•

The overall crystal structures of hP0ex and rP0ex are similar.

•

Certain regions in hP0ex show high flexibility relative to rP0ex.

•

The surface area of hP0ex is larger than the surface area of rP0ex.

•

Molecular dynamics simulation of mutant H10P indicates the interrupted
intra-molecular disulfide bonds.

•

The

presence

of

the

maltose

binding

protein

facilitates

the

crystallization of hP0ex.

7.2 Future directions
7.2.1 Future directions of the HIV-1 protease project
•

Measure the Km and kcat of MDR769 HIV-1 protease with nine different
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natural substrate peptides.
•

Chemically synthesize more potential HIV-1 protease inhibitors to
overcome the drug resistance issue.

•

Test the inhibitory activity of the synthesized drug candidates against
both the WT and MDR HIV-1 protease.

•

Perform in silico screening to identify potent drug candidates against
MDR769 HIV-1 protease.

•

Crystallize other three strains of MDR HIV-1 proteases in the lab.

•

Cocrystallize the nine natural substrate peptides to reveal the substrate
envelope of the MDR769 HIV-1 protease.

•

Cocrystallize the FDA approved HIV-1 protease inhibitors with the
MDR769 HIV-1 protease to reveal the structural basis of drug
resistance against the FDA approved inhibitors.

•

Based on the crystal structure of the MDR769 HIV-1 protease inhibitor
complexes, further molecular dynamics simulation is performed to
reveal the mechanism of drug resistance.

7.2.2 Future directions of the human myelin protein zero project
•

Perform in silico molecular dynamical simulations of mutants based on
the extracellular domain of WT human myelin protein zero to reveal the
molecular mechanism of Charcot-Marie-Tooth disease 1B.

•

Run in silico screening and docking to look for small molecules with
high binding affinities to the extracellular domain of WT human myelin
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protein zero. The binding of these small molecules may alter the
conformation of MPZ and lead to alleviation of the signs and symptoms
of Charcot-Marie-Tooth disease 1B.
•

Continue crystallization trials of the extracellular domain of the human
myelin protein zero with mutations at H10P and R69H.

•

Stain the human myelin protein zero with mutations H10P and R69H
using Congo red to examine the presence of amyloid that shows
characteristic green birefringence under polarized light.

•

Perform the X-ray scattering diffraction studies on human myelin protein
zero with mutations H10P and R69H to look for the signagure diffraction
pattern of amyloid at wavelength 4.7 Å and 10 Å.
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PROJECT 1
Under drug selective pressure, emerging mutations render HIV-1 protease
drug resistant, leading to antiretroviral therapy failure. The multidrug-resistant
isolate 769 (MDR769) of HIV-1 protease, with resistance mutations at residues
10, 36, 46, 54, 62, 63, 71, 82, 84, 90, was selected for the present study to
investigate the drug resistance issue.
Ten additional mutations were introduced into to MDR769 HIV-1 protease
to study the structural influences introduced by these mutations. We obtained
crystal structures of four variants (I10V, A82F, A82S and A82T) of MDR769
HIV-1 protease. All these mutations failed to further open the flaps and further
expand the active site cavity of MDR769 HIV-1 protease, which was
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characterized by wide open flaps and expanded active site cacity. The
conserved flaps and active site cavity, despite the introduction of additional
mutations, indicated that the MDR769 HIV-1 protease represented the end
stage form of HIV-1 protease. In addition, these crystal structures provided the
first structure based evidence for the mutation induced conformational
changes in the 80s loops of the HIV-1 protease apo-enzyme, although the flap
and active site cavity were not changed dramatically. The alternate
conformations of Pro81 (proline switch) in the I10V mutant and the side chain
of Phe82 with flipped-out conformation in A82F mutant showed distorted
S1/S1’ binding pockets that caused loss of contacts and unstable binding of
the inhibitors. Similarly, the mutants A82S and A82T showed distortion in the
S1/S1’ binding pockets due to local changes in the electrostatics caused by the
mutation from non-polar to polar residues.
Molecular mechanics studies performed to understand the wide-open
nature of the MDR769 HIV-1 protease flaps showed that the MDR protease
exhibited a state of conformational rigidity with respect to the flap closure
compared to that of the wild type protease. This suggested that the
accumulation of mutations changed the structure of the MDR HIV-1 protease
and resulted in a cumulative steric hindrance during the flap closure. Our
studies showed that modeling a substrate (Gag – Capsid) into the active site
cavity of the MDR protease did not result in flap closure. Since flap closure
was crucial in protease inhibitor binding, the conformational rigidity of MDR
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protease might represent a novel mechanism for multidrug-resistance of the
MDR protease. In addition, our molecular dynamics simulation revealed the
realignment of the substrate peptide in the MDR769 HIV-1 protease, making it
less accessible to the Asp25 and Asp125 amino acid residues in the active site.
This finding indirectly indicated the reduced catalytic activity of MDR769 HIV-1
protease in substrate cleavage compared to that of the WT HIV-1 protease.
The IC50 values of the FDA approved HIV-1 protease inhibitors and the
library of reduced CA/p2 peptide analogs were measured. The results
indicated that the reduced peptide analogs bind to the MDR769 HIV-1
protease and WT HIV-1 protease with equal affinity, while the FDA approved
inhibitors showed reduced binding affinity to the MDR769 HIV-1 protease
compared to that of WT HIV-1 protease. The enzyme measurements
demonstrated that lopinavir was the least resistant HIV-1 protease inhibitor
and that reduced peptide P1’F was comparable to FDA approved inhibitors
from the aspect of the inhibitory activity against HIV-1 protease.
Based on these studies, a library of potential drug candidates against
HIV-1 protease was proposed to overcome the drug resistance issue. These
drug candidates are being synthesized in the lab and will be evaluated in the
future.
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PROJECT 2
The wild type extracellular domain of human myelin protein zero (hP0ex)
fused with maltose binding protein (MBP) was crystallized to investigate the
molecular mechanism of Charcot-Marie-Tooth disease subtype 1B. Based on
the wild type structure of the extracellular domain of the human myelin protein
zero, five clinically important mutants were further structurally investigated in
details. The molecular pathology was proposed for these mutants individually.
The relationship between amyloidosis disease and CMT1B is being further
explored. From a technical point of view,the WT hP0ex MBP fusion structure
was another example of crystallographic studies facilited by the presence of a
purification and crystallization protein tag, the maltose binding protein.
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